NCCN 2017 ANNUAL REPORT

Transcription

1

2 It s the human story behind our growth that really matters. It speaks to the relevance and influence of the NCCN Guidelines. We now have more than one million people who have free access to the most up-to-date, evidence-based standards for the treatment of nearly every type of cancer. Robert W. Carlson, MD, Chief Executive Officer, NCCN, on reaching one-million-user milestone in October 2017 NCCN 2

3 DIRECTORS AND CHIEF EXECUTIVE OFFICER Making a world of difference for patients with cancer The National Comprehensive Cancer Network (NCCN ) has long insisted that where you live shouldn t determine whether you live. Grounded in that motto and impelled by our fundamental mission to improve the quality, effectiveness, and efficiency of cancer care so patients can live better lives, our alliance of Member Institutions and our staff members challenge themselves each and every day to make the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) and the care recommended therein more accessible. NCCN Timothy J. Eberlein, MD Chair, NCCN Board of Directors (left) Robert W. Carlson, MD Chief Executive Officer, NCCN (right) 3

4 Through expert clinical recommendations, continuing education programs, global outreach, research initiatives, policy work, and our multitude of multistakeholder collaborations, NCCN has set the standard of cancer care for nearly a quarter century. Our legacy speaks for itself. In October 2017, we hit a milestone, onemillion registered users of the NCCN Guidelines! Moreover, the NCCN Guidelines were downloaded more than eight million times in 2017 a 16% increase over 2016 and a 25% increase across two years. It s the human story behind these numbers that really counts. Today, there are more than 15.5 million cancer survivors living in the United States alone. By providing free access to the recommendations in the NCCN Guidelines to people around the globe, our vision is to see that the number of cancer survivors keeps growing worldwide. NCCN s efforts to increase accessibility also include 142 translations of the NCCN Guidelines, 24 regional adaptations, as well as resource-stratified guidelines tailored to low- and mid- resource regions throughout the world. NCCN Broadening the access to appropriate treatment and supportive care, together with the Africa Cancer Coalition, American Cancer Society, and Clinton Health Access Initiative, we launched the NCCN Harmonized Guidelines for Sub-Saharan Africa in November. These Guidelines represent both the optimal care these countries aspire to provide and pragmatic approaches outlining effective treatment options for resourceconstrained settings. 4

5 Indeed, patients are paramount to our mission. Complementing the eight million downloads of NCCN Guidelines in 2017, NCCN, with support from the NCCN Foundation published 24 new and updated NCCN Guidelines for Patients, bringing the total library to 39. More than 395,000 people accessed these patient-friendly translations of our clinical guidelines in 2017 with more than eight million page views. From the more than 500,000 registered users in the United States to the five in Togo, we are honored to play a part in upholding NCCN s mission to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. We thank all involved for making a difference in the lives of people with cancer. NCCN With best regards, Timothy J. Eberlein, MD Chair, NCCN Board of Directors Spencer T. and Anne W. Olin Distinguished Professor Director of The Alvin J. Siteman Cancer Center Bixby Professor and Chair of Surgery of the Department of Surgery Washington University Robert W. Carlson, MD Chief Executive Officer, NCCN 5

6 National Comprehensive Cancer Network is an alliance of 27 leading cancer centers devoted to patient care, research, and education. WHY WE EXIST To improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. OUR VISION To be the world s leader in defining and advancing high-quality, high-value cancer care. NCCN 6

7 NCCN MEMBER INSTITUTIONS Omaha, Nebraska Stanford, California Case / University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio City of Hope Comprehensive Cancer Center Los Angeles, California Chicago, Illinois Phoenix/Scottsdale, Arizona Jacksonville, Florida Rochester, Minnesota Memorial Sloan Kettering Cancer Center New York, New York Birmingham, Alabama La Jolla, California Boston, Massachusetts Durham, North Carolina Tampa, Florida The Ohio State University - James Cancer Hospital and Solove Research Institute San Francisco, California Aurora, Colorado Ann Arbor, Michigan NCCN Columbus, Ohio Philadelphia, Pennsylvania Salt Lake City, Utah Fred Hutchinson Cancer Research Center/ Roswell Park Comprehensive Cancer Center Buffalo, New York St. Louis, Missouri Houston, Texas University of Wisconsin Carbone Cancer Center Madison, Wisconsin Seattle, Washington St. Jude Children s Research Hospital/ Nashville, Tennessee Yale Cancer Center/ Smilow Cancer Hospital Baltimore, Maryland Memphis, Tennessee New Haven, Connecticut 7

8 GUIDELINES WE LIVE BY Paramount to ensuring patient access to quality care is empowering patients and providers with evidence-based information for use in the decision-making process. Our mission to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives can only be realized through unwavering dedication to providing all oncology stakeholders with the utmost reliable and upto-date treatment information. NCCN makes this possible through the publication and upkeep of the library of NCCN Guidelines and derivative products. First developed by visionary leaders in 1995 for eight cancer types, NCCN Guidelines provide sequential management decisions and interventions for the treatment of 97% of cancers affecting patients in the United States. Now, as before, the goal of these Guidelines is to ensure that all patients have access to the optimal outcomes for their disease. Today, we offer 68 NCCN Guidelines documenting evidencebased treatment interventions and management, as well as Guidelines for detection, prevention, and risk reduction; supportive care; and age-related recommendations. Developed by more than 1,200 NCCN Member Institution volunteers seated on 53 panels, each NCCN Guidelines document is updated at least annually to reflect the latest advances in treatment. In 2017, we reached new records, with as many as nine interim updates to NCCN Guidelines for certain diseases. Our panel members are multidisciplinary, disease-specific sub-specialists who are both clinicians and researchers, as well as patients and patient advocates. Grounded in our mission, NCCN develops and maintains a host of derivative resources of the NCCN Guidelines. Products like the library of NCCN Compendia, NCCN Guidelines with NCCN Evidence Blocks tm, and the NCCN Chemotherapy Order Templates (NCCN Templates ) aid in decision-making. Moreover, throughout the year, NCCN offers in-person and online education programs, delivering knowledge of the latest advancements in cancer care to nearly 14,000 learners. Through efforts of the NCCN Foundation, patients are able to access adapted, patient-friendly versions of NCCN Guidelines recommendations, empowering them to make informed decisions about their treatment plans. DERIVED FROM THE NCCN GUIDELINES NCCN Guidelines with NCCN Evidence Blocks tm NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework tm ) NCCN Harmonized Guidelines tm NCCN Drugs & Biologics Compendium (NCCN Compendium ) NCCN Biomarkers Compendium NCCN Radiation Therapy Compendium tm NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC tm ) NCCN Chemotherapy Order Templates (NCCN Templates ) NCCN Guidelines for Patients NCCN Quick Guide tm Series International Adaptations NCCN Educational Events and Programs NCCN Clinical and Business Resources NCCN 2017 ANNUAL REPORT NCCN 8

9 Table of Contents NCCN NCCN 49 Executive Committee 49 NCCN Board of Directors 50 NCCN Senior Management Team 51 NCCN Committees, Groups, and Panels 88 NCCN Staff NCCN 91 Patient and Caregiver Resources 95 NCCN Foundation Young Investigators Awards 98 NCCN Foundation Leadership NCCN Foundation Donors 9

10 NCCN NCCN 2017 ANNUAL REPORT Photo Credit: 10

11 ACCESS to life-saving treatment guidelines By compiling every recommendation for radiation therapy in one place, we ve made it significantly easier for radiation oncologists to stay upto-date on the very latest recommendations, regardless of how many different cancer types they treat. - Robert W. Carlson, MD, Chief Executive Officer, NCCN A complete compendium to aid in cancer care Nearly two-thirds of patients with cancer receive radiation therapy one of the most common treatments for cancer in the United States. To provide a definitive source for radiation therapy recommendations, NCCN announced the availability of the NCCN Radiation Therapy Compendium in early This compendium is part of NCCN's ongoing effort to always provide the most pertinent data on emerging treatment practices in the clearest, most efficient way possible. Hosting a single access point for all radiation therapy recommendations within the library of NCCN Guidelines, the newest addition to the our Library of Compendia was completed in October 2017 just seven months from the publication of the first chapters. Today, 42 Guidelines with radiation therapy recommendations are featured within the NCCN Radiation Therapy Compendium, providing radiation oncologists with the specific, cutting-edge information they need, without requiring them to sift through any extraneous information. NCCN 11

12 Forward progress in the face of cancer The library of NCCN Guidelines cover more than 97% percent of cases in the United States, yet we remain steadfast in our mission to ensure that patients have access to the best care for their disease type, no matter how complicated or rare. In 2017, NCCN published new NCCN Guidelines for AIDS-Related Kaposi Sarcoma, bringing the total library to 68 Guidelines. The treatment recommendations for AIDS-Related Kaposi Sarcoma were derived from one of the eight original NCCN Harmonized Guidelines for Sub-Saharan Africa. Subsequent to the growth of the NCCN Guidelines library, derivative products update throughout the year to reflect the changes in the Guidelines algorithms. In addition to the complete NCCN Radiation Therapy Compendium, in 2017 NCCN maintained 40 out of 48 possible NCCN Guidelines with NCCN Evidence Blocks, more than 3,200 NCCN Compendium Listings, 1,170 NCCN Templates, and 1,170 NCCN Imaging AUC entries for 51 cancer types. NCCN One in a million Of significance in 2017, was achieving the milestone of one million registered users of the NCCN Guidelines on NCCN.org. These users downloaded the NCCN Guidelines more than eight million times from NCCN.org and the Virtual Library of NCCN Guidelines mobile app a 16% increase over 2016 and a two-year increase of 25%. 12

13 NCCN GUIDELINES DOWNLOADS IN 2017 (MILLIONS) NCCN In 2017, NCCN Guidelines were downloaded by more than 2.6 million unique users. This increase speaks to the growing influence of and demand for NCCN Content worldwide. Defining optimal care with Catgories of Preference In the 2017 NCCN Guidelines User Survey, 85% of U.S. respondents said they would prefer to have optimal treatments outlined in the Guidelines. In September, NCCN began publishing Categories of Preference for drugs and biologics within the Guidelines, beginning with Multiple Myeloma. While all recommendations within the Guidelines are considered appropriate, Categories of Preference distinguish between preferred interventions, other recommended interventions, and those useful in certain circumstances. 13

14 The goal of the Categories is to stratify Guidelines to clarify panel and institutional preferences for interventions, to provide guidance to users of the Guidelines on which recommendations are considered optimal, and to continue to provide a wide range of recommendations to meet varying clinical circumstances and patient preference. To view Dr. Carlson, visit NCCN.org/annualreport A 360 view of cancer care Launched during the 2016 Annual Conference, JNCCN360 is a family of tumor-specific microsites providing users with carefully curated content tailored specifically to NCCN s audience. JNCCN360 is the latest resource from JNCCN Journal of the National Comprehensive Cancer Network. In 2017, JNCCN360 microsites were available for Multiple Myeloma and Breast, Kidney, and Non-Small Cell Lung Cancers. JNCCN is a peer-reviewed, Pub-Med indexed journal with a circulation of more than 25,000, featuring original health services research from investigators from NCCN Member Institutions and around the world, as well as insights on NCCN Guidelines updates, and insightful commentary from leading experts in oncology. NCCN Dr. Carlson, CEO of NCCN, on JNCCN

15 2017 Clinical Information Metrics IN 2017, 68 NCCN GUIDELINES CONTAINING 183 ALGORITHMS UPDATED 150 TIMES WERE DEVELOPED BY 1,355 NCCN MEMBER INSTITUTION EXPERTS VOLUNTEERING ON 53 GUIDELINES PANELS. NCCN 40 NCCN GUIDELINES WITH NCCN EVIDENCE BLOCKS tm 3,256 ACTIVE NCCN COMPENDIUM RECORDS 1,140 NCCN BIOMARKERS COMPENDIUM RECORDS 1,170 NCCN TEMPLATES PUBLISHED 15 NCCN FRAMEWORK tm 8 NCCN HARMONIZED GUIDELINES tm 51 NCCN IMAGING AUC tm CANCER TYPES As of December 31,

16 NCCN NCCN 2017 ANNUAL REPORT 16

17 ACCESS to ground-breaking research By highlighting technological advances and multidisciplinary collaboration, we hope to encourage the widespread adoption of best practices for reducing costs and improving quality in breast cancer patient care. - Susan Most, RN, MBA, Director of Clinical Operations, NCCN ORP Funding quality improvement projects in breast cancer In November 2017, the NCCN Oncology Research Program (ORP), in collaboration with Pfizer, funded nine projects representing four NCCN Member Institutions and other cancer centers throughout the country for projects that use clinical care pathways to implement quality improvement initiatives along the continuum of care for underserved patients with breast cancer. A unique collaboration between ORP and Pfizer Global Medical Grants, the project sought proposals from both NCCN Member Institutions, as well as other academic and community hospitals throughout the United States. More than 90 letters of intent were received. Following are the approved proposals: NCCN East Carolina University; Improving the Quality of Breast Cancer Care in an Underserved Rural Setting Emory ; Care Pathway Development, 17

18 Implementation and Assessment to Improve Outcomes in African American (AA) Breast Cancer Patients Intermountain Healthcare; Improving Clinical Pathways and Care Delivery in Breast Cancer Johns Hopkins ; Reducing Discontinuation Rate of Adjuvant Endocrine Therapy through Symptom Monitoring and Management Johns Hopkins ; Optimizing Delivery of Neoadjuvant Chemotherapy to Breast Cancer Patients who are Appropriate Candidates at Johns Hopkins Northwestern University Feinberg School of Medicine; Innovating Patient-Facing Care Pathways in Breast Cancer using the 4R model, 4R = Right Information / Care / Patient / Time Northwestern University Feinberg School of Medicine; Statewide Learning Collaborative to Improve Adherence to Breast Cancer Guidelines Roswell Park Alliance Foundation; Breast Cancer Pathways Impact on Shared Decision Making and Patient Experience In Academic and Community Practice University of Nebraska Board of Regents dba University of Nebraska Medical Center; Clinical Pathway for the Timely & Appropriate Treatment and Support of Young Women Diagnosed with Breast Cancer NCCN Bringing breakthroughs to lung cancer Two NCCN Member Institution investigators received ORP grants in March for the study of osimertinib in patients with EGFRm+ Non-Small Cell Lung Cancer, funded through a collaborative scientific relationship with AstraZeneca. 18

19 The following studies were awarded funding: Daniel Gomez, MD, MD Anderson Cancer Center, Randomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR) Pasi A. Jänne, MD, PhD, Dana-Farber/Brigham and Women s Cancer Center Massachusetts General, A Phase 2 Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer Elizabeth Gerstner, MD Massachusetts General Milestones in brain cancer treatment Glioblastoma is the most common malignant primary brain tumor, yet overall outcomes for patients diagnosed with glioblastoma is very low despite aggressive treatment. NCCN In 2017, Elizabeth Gerstner, MD, of Massachusetts General Hospital Cancer Center, dosed the first patient in a clinical trial funded through ORP to study the effectiveness of bavituximab in patients with glioblastoma. Annual poster session continues to grow In 2017, the General Poster Session held during the NCCN Annual Conference had yet another year of record participation; 85 presenters, including six NCCN Young Investigator Awardees from The 2017 studies included research on the following topics: 19

20 Clinical Oncology (all phases) Pre-Clinical Oncology Epidemiology/Risks Correlative/Genomic Best Practices in Implementation and Use of Clinical Practice Guidelines Quality Improvement Outcomes and Health Services Research BIOinformatics/Information Technology Sciences Select poster abstracts were also featured in a supplement issue of JNCCN. NCCN Sharing resources among Member Institutions NCCN ORP promotes collaborative research among NCCN Member Institutions in various ways, including the management of the NCCN Shared Resources Database. Scientists and investigators at 18 NCCN participating cancer centers access the database and the resources therein that will improve the ability to conduct meaningful research. Through the database, investigators share more than 230 unique assets, such as complex technologies, instrumentation facilities, human tissue specimens, animal models, and specialized databases. 20

21 2017 Oncology Research Metrics 2 GRANTS AWARDED IN COLLABORATIVE RESEARCH PROJECTS 18 NUMBER OF NCCN MEMBER INSTITUTIONS PARTICIPATING IN SHARED RESOURCES 85 ANNUAL POSTER SESSION PRESENTERS 114 PUBLISHED ABSTRACTS 239 SHARED RESOURCES AVAILABLE TO PARTICIPATING NCCN MEMBER INSTITUTIONS MESSAGE 2,357 FROM THE CHAIR TERMS WITHIN THE NCCN INFORMED CONSENT LANGUAGE DATABASE NCCN As of December 31,

22 NCCN BUSINESS RESOURCES & ACCESS NCCN TO 2017 LIFE-SAVING ANNUAL REPORT TREATMENT GUIDELINES Photo Credit: 22

23 Providing ACCESS to recommendations at point of care Collaborations to ensure access Paramount to ensuring that patients have access to high-quality cancer care is providing access to up-to-date cancer treatment recommendations for all stakeholders in oncology. NCCN To that end, NCCN upholds long-standing relationships and continues to build new collaborations with some of the most influential health information technology (HIT) vendors around the world. NCCN encourages and applauds the inclusion of NCCN Guidelines and derivative content in HIT and decision-support tools in order to not only improve care for patients, but also to provide for quality assessment initiatives. In 2017, NCCN embarked on several new and expanded collaborations. Among these are new collaborations with Evinance Innovation, Inc., 23

24 Reproduced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) for B-Cell Lymphomas V and T-Cell Lymphomas V National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NCCN 2017 ANNUAL REPORT Access the NCCN Guidelines for Soft Tissue Sarcoma mobile app Access the NCCN Guidelines B-Cell Lymphomas mobile app NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) B-Cell and T-Cell Lymphomas Mantle Cell Lymphoma Peripheral T-Cell Lymphoma, Noncutaneous Mycosis Fungoides/Sezary Syndrome NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Soft Tissue Sarcoma Access the NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma mobile NCCN.org app Access the NCCN Guidelines T-Cell Lymphomas mobile app NCCN.org Version October 31, 2017 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCCN.org Version 2017 Version October 23, 2017 ION Solutions, a part of AmerisouceBergen, and Meditech Information Technology Inc. to integrate the NCCN Guidelines and/or NCCN Templates into their technologies allowing for access to evidence-based recommendations through EHR systems and chemotherapy treatment management modules. In addition, NCCN extended the term and expanded the scope of its collaboration with multiple licensees committed to working with NCCN to improve cancer care by providing expanded access for clinicians and other stakeholders to NCCN recommendations at point of care, such as with: Change Healthcare, CVS Pharmacy Inc., evicore Healthcare, IBM Watson, and McKesson Speciality Health. In continuation of its support of the U.S. Department of Health and Human Services call for standardization of cancer care information across all electronic platforms, NCCN, a Centers for Medicare & Medicaid Services (CMS) recognized provider-led entity for development of imaging AUC, continues to work multiple organizations for inclusion of the NCCN Imaging AUC tm in HIT, such as with: AIM Speciality Health, Intermountain Insights, Inc., evicore Healthcare, McKesson Speciality Health, MedCurrent, National Decision Support Company, and New Century Health. Distribution of NCCN Content NCCN NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. In addition to the inclusion of NCCN Content in HIT, NCCN recognizes and appreciates the significance of ensuring that providers are able to access Guidelines recommendations in whatever format they use. 24

25 To do so, NCCN works with outside organizations for dissemination of NCCN Content through print copies of the NCCN Guidelines, NCCN Pocket Guidelines, NCCN Flash Cards of select content from the NCCN Guidelines and Compendia, and sponsorship of the NCCN Virtual Library of NCCN Guidelines Mobile Application. Through such collaborations, in 2017, 82,000 sponsored versions of the Guidelines were distributed. NCCN Corporate Council The NCCN Corporate Council is an important resource for the development and expansion of NCCN programs and resources. NCCN offers membership in the NCCN Corporate Council to significantly enhance collaborative efforts between pharmaceutical, biotechnology, and diagnostic companies and NCCN, and thus better serve patients. NCCN In 2017, NCCN hosted two NCCN Corporate Council meetings that engaged representatives from industry in order to deliberate patient and provider needs and identify avenues of support for such initiatives. Patient safety we ve got that in the bag In continuance of the international campaign for patient safety, the NCCN Just Bag It! campaign moved forward in 2017, bringing to light the importance of delivering vincristine in IV mini-bag to eliminate the risk of a fatal medical error. In August 2017, NCCN announced it reached its goal of 25

26 100 cancer centers and hospitals signing on to the campaign and adopting policies in line with the NCCN Guidelines. MiKaela Olsen, MS, APRN- CNS, AOCNS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Moreover, MiKaela Olsen, MS, APRN-CNS, AOCNS, an oncology nurse at The Sidney Kimmel at Johns Hopkins, one of the NCCN Member Institutions, spearheaded a center-wide effort to administer vincristine via mini IV-drip bags, the results of which she presented at the Oncology Nursing Society Annual Congress in May. After successful implementation in pediatric oncology at Johns Hopkins Hospital, the change was put into effect in adult oncology following thoughtful design of the step-by-step procedure, policy revisions, and collaboration between nursing and pharmacy. Our staff feel confident that this new procedure is safe and that it is absolutely the right thing to do to prevent patient harm. Once we made the change, we did not look back. Eliminating the risk of harm was our number one priority, said MiKaela Olsen, MS, APRN-CNS, AOCNS, The Sidney Kimmel at Johns Hopkins on implementing the NCCN Just Bag It! campaign. NCCN More information about the Just Bag It campaign and a list of facilities who have reported a change to their vincristine administration practices are available at NCCN.org/justbagit. 26

27 2017 Business Resources & Public Awareness Metrics 12 CANCER TYPES PUBLISHED AS NCCN POCKET GUIDELINES 38 NCCN TRENDS tm REPORTS IN HIT LICENSEES OF NCCN CONTENT 54 PRESS RELEASES DISTRIBUTED 73 CORPORATE COUNCIL MEMBERS 82,500 TOTAL NUMBER OF NCCN POCKET GUIDELINES 127 DISTRIBUTED FLASH UPDATES tm SENT IN 2017 NCCN 510,306 EBULLETIN SUBSCRIBERS As of December 31,

28 NCCN ACCESS NCCN TO 2017 LIFE-SAVING ANNUAL REPORT TREATMENT GUIDELINES 28

29 Ensuring ACCESS to appropriate care around the globe Taking a stand against poor outcomes in Africa On November 8, NCCN debuted its new NCCN Harmonized Guidelines for Sub-Saharan Africa the outcome of a much-anticipated and groundbreaking collaboration between the Africa Cancer Coalition, American Cancer Society, Clinton Health Access Initiative, IBM, and NCCN. Taking into account the skyrocketing cancer rates and unique care circumstances of the region, the Harmonized Guidelines outline two tiers of appropriate treatment recommendations based on the parent NCCN Guidelines: NCCN Breast Cancer Cervical Cancer Prostate Cancer B-cell Lymphomas Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Kaposi Sarcoma Adult Cancer Pain Palliative Care Dr. Robert Carlson presents the new NCCN Harmonized Guidelines tm for Sub-Saharan Africa during the AORTIC Conference in Kigali, Rwanda. 29

30 It was a gratifying and inspiring experience to collaborate with, and learn from, our Sub- Saharan colleagues, who do hands-on work solving problems for patients every day. Working together, we were able to distill the most important elements of care management, and prioritize treatments that provide effective outcomes even when resources are limited. - Wui-Jin Koh, MD, Seattle Cancer Care Alliance In many ways, this is an initiative modeled after the success of past HIV efforts, and also necessary because of them. As life expectancy increases in the area, more and more people are being diagnosed with various cancers. This project also inspired the creation of brand new NCCN Guidelines for AIDS-related Kaposi sarcoma, which accounts for 12% of cancer diagnoses for people living with HIV in the United States, but occurs much more frequently in Sub-Saharan Africa. NCCN continues to work with oncology specialists around the world to identify the need for harmonized guidelines throughout other low-resource areas. Providing a forum for global deliberation NCCN hosted a Global Patient Advocacy Engagement Roundtable before ESMO 2017 in Madrid, Spain. This multi-stakeholder Global Roundtable assembled patient advocates, physicians, and policy experts to discuss best practices in global patient advocacy efforts to ensure that patients are involved at all levels of health care decision-making. Moderated by Robert W. Carlson, MD, the panel discussed variations in patient advocacy efforts and patient access to quality cancer care. NCCN In October, in conjunction with the NCCN 12 th Annual Congress: Hematologic Malignancies tm in San Francisco, California, NCCN held its inaugural NCCN Global Academy for Excellence & Leadership in Oncology tm : School of Pharmaceutical & Biotech Business. Moderated by Dr. Carlson, this event convened eight global oncology stakeholders, representing providers, as well as patient advocates to discuss the biggest challenges facing the delivery of and access to high-quality cancer care throughout the world. 30

31 Mihaela Militaru, Merck KGaA; Cathy Trzaskawka, Bristol-Myers Squibb; & Piotr Wysocki, MD, PhD, Jagiellonian University Medical College Hospital & President, Polish Society of Clinical Oncology, speak during NCCN's inaugural Global Academy program. Global corporate council 2017 marked the third year of the NCCN Global Corporate Council. Convening 20 members, the Council is an important resource for the development and expansion of NCCN global programs by providing the opportunity for open dialogue, collaboration, and support of NCCN s mission and vision outside the United States. In 2017, NCCN hosted its annual Global Corporate Council meeting in conjunction with the NCCN Annual Conference in Orlando. Growing global influence More than 46% of the one million registered users of NCCN Guidelines on NCCN.org report that they live outside the United States. Indeed, the influence of NCCN Content continued to gather momentum throughout all regions of the world, with more than 2.4 million Guidelines downloaded from NCCN.org (excluding the mobile app) from outside of the States in NCCN Dr. Carlson moderates NCCN Global Academy Roundtable featuring experts involved in development of NCCN Guidelines and their global adaptations. To ensure that providers and patients around the world have access to the most up-to-date standards in cancer care, NCCN is committed to maintaining and growing a library of resource stratified guidelines, global adaptations, harmonizations, and translations of NCCN Guidelines. NCCN published seven new and updated NCCN Framework. Originally launched in late 2015, these tools outline the most optimal treatment options for patients with cancer, based on four levels of available resources. In 2017, the library of NCCN Framework grew to 16, covering 75% of global cancer cases. 31

32 NCCN GUIDELINES DOWNLOADS BY COUNTRY IN 2017 NCCN Additionally, NCCN published 55 new translations of the NCCN Guidelines into Chinese, French, German, Italian, Korean, Portuguese, and Spanish. NCCN collaborated with global stakeholders to publish the following regional adaptations of NCCN Guidelines: Asia Consensus Statements for NCCN Guidelines for Bladder, Kidney, and Prostate Cancers 32

33 Staff from NCCN and Kidney Cancer Association present new translations of the NCCN Guidelines for Patients : Kidney Cancer during ESMO Latin America adaptation of the NCCN Guidelines for Multiple Myeloma and Colon, Prostate, and Rectal Cancers Middle East and North Africa adaptations of the NCCN Guidelines for Breast, Hepatobiliary, Lung, Colon, and Prostate Cancers, and Lymphomas Spain adaptations of the NCCN Guidelines for Breast and Colon Cancers As recognized thought leaders in global cancer care, NCCN was invited to present and/or exhibit at a number of oncology conferences throughout the year: International Patient Empowerment Congress, Warsaw, Poland ESMO 2017, Madrid, Spain International Forum for Quality Cancer Care, Beijing, China AORTIC Conference, Kigali, Rwanda Second Indian Cancer Congress, Bengaluru, India NCCN These engagements allowed NCCN leadership and staff to educate a diverse audience on the resources available to them for optimal cancer care, such as NCCN Harmonized Guidelines and NCCN Framework, reinforcing NCCN s position as a leading influence on oncology policy and exemplifying its mission to improve the lives of patients with cancer, no matter where they live. 33

34 2017 Global Programs Metrics 16 NCCN FRAMEWORK tm AVAILABLE 8 NCCN HARMONIZED GUIDELINES tm AVAILABLE 20 NCCN GLOBAL CORPORATE COUNCIL MEMBERS 24 NCCN GUIDELINES ADAPTATIONS 142 NCCN GUIDELINES TRANSLATIONS 46 % OF REGISTERED USERS OF NCCN GUIDELINES FROM OUTSIDE THE U.S. NCCN 479,330 EX-U.S. REGISTERED USERS OF NCCN GUIDELINES ON NCCN.ORG 180+ COUNTRIES WHERE NCCN GUIDELINES ARE ROUTINELY DOWNLOADED As of December 31,

35 NCCN ACCESS NCCN TO LIFE-SAVING 2017 ANNUAL REPORT TREATMENT GUIDELINES 35

36 Influencing policy to ensure ACCESS to high-quality care Setting the stage for discussion As part of its ongoing policy summit series, NCCN brought together key opinion leaders and decision-makers in the oncology space to discuss some of the most pertinent policy issues in cancer care. The following policy summits were held in 2017: NCCN Ensuring Patient Access and Safety in Cancer Care Redefining Quality Measurement in Oncology Addressing Survivorship in Cancer Care (Patient Advocacy Summit) NCCN Policy Summit: Redefining Quality Measurement in Oncology, September 2017 NCCN worked closely with multiple patient advocacy organizations in the planning and execution of the Patient Advocacy Summit, including: American Society for Therapeutic Radiation Oncology, Cancer Hope Network, Cancer Support Community, Children s Cause for Cancer Advocacy, Fight Colorectal Cancer, Florida Society of Clinical Oncology, Kidney Cancer Association, Leukemia and Lymphoma Society, Live By 36

37 Living, LiveSTRONG, Living Beyond Breast Cancer, LUNGevity, National Alliance of State Prostate Cancer Coalitions, National Ovarian Cancer Coalition, and UsTOO. For detailed summaries of the policy summits, visit NCCN.org/policy. The word survivor may imply that treatment has concluded, but for many cancers, survivors actually need ongoing treatment for the rest of their lives. Some people find the word too passive. They may, understandably, prefer to call themselves warriors. - Yalek Biru, the event s keynote speaker who was diagnosed with Multiple Myeloma 22 years ago. Exploring disparities in survivorship Living through and beyond a cancer diagnosis has profound effects on a person s well-being physically, psychologically, socially, economically, and spiritually. On December 1, 2017, NCCN convened various stakeholders to explore the significant and unique challenges facing survivors today, as well as those who care them particularly in a time of such uncertainty in health care policy. The Annual Patient Advocacy Summit featured two roundtable panels, as well as informational presentations by national patient advocates, featuring resources available to patients today. Of particular note was the topic of disparities, specifically regarding the different needs of urban and rural populations and people across socioeconomic statuses. When it comes to racial minorities, panelists were concerned about gaps in data, and agreed more outreach and study is needed for underserved communities. The panelists also discussed the impact of aging baby boomers and the growing survivorship population. NCCN 37

38 It s very important to determine who handles the ongoing coordination of care for survivors. Care management generally shifts to primary care physicians, but it needs to be done in an integrated way so that survivors have all of their health care needs addressed, said Crystal Denlinger, MD, FACP, Chair of the NCCN Guidelines Panel for Survivorship. Crystal Denlinger, MD, FACP, Chair of the NCCN Guidelines Panel for Survivorship Echoing the patient voice in Washington, DC NCCN is committed to ensuring access to high-quality, high-value care for patients with cancer and thus engages policy makers, initiates multistakeholder discussions, and tracks related policy initiatives and legislation posted in the Federal Registry. In 2017, NCCN authored several policy statements highlighting significant barriers, as well as areas of opportunity to ensure that heath care accessibility and affordability goals are met within the cancer care space. NCCN embarked on new relationships with policy makers and influencers in Washington, DC, to ensure that constituents were aware of NCCN resources available to them from the alliance. Moreover, NCCN continued to provide comment on rules and quality measurement proposals, including: NCCN Patient Protection and Affordable Care Act HHS Notice of Benefit and Payment Parameters for 2019 Proposed Rule November 2017 CMS 2018 Medicare Physician Fee Schedule (PFS) Proposed Rule September 2017 CMS 2018 Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule September

39 CMS 2018 Quality Payment Program (QPP) Proposed Rule August 2017 Wisconsin Physician Services (WPS) Proposed Draft for Local Coverage Determination June 2017 Patient Protection and Affordable Care Act Market Stabilization Proposed Rule March 2017 To read more about NCCN policy positions, comment letters, and initiatives visit NCCN.org/policy. Payer collaborations To facilitate patient access to quality cancer care as recommended by the NCCN Guidelines, NCCN collaborates with public and private payers, employers, pharmacy benefit managers, and related organizations to allow for effective and efficient use of the NCCN Guidelines and their derivatives for the development, implementation, and assessment of coverage and quality policies and programs. NCCN Since 2008, the NCCN Compendium has been recognized by CMS as a mandated reference for establishment of coverage policy for the use of drugs and biologics in cancer care. Moreover, following CMS recognition of NCCN as a provider-led entity for imaging AUC in 2016, NCCN fostered collaborations to ensure that recommendations within the NCCN Imaging AUC are integrated into leading decision-support platforms, safeguarding access to evidence-based imaging recommendations at the point of care. 39

40 2017 Policy Initiatives Metrics 496 POLICY SUMMIT ATTENDEES 10 COMMENT LETTERS SUBMITTED NCCN 4 ARTICLES PUBLISHED 3 ONCOLOGY POLICY PROGRAMS HOSTED As of December 31,

41 NCCN EDUCATIONAL CLINICAL EVENTS INFORMATION ACCESS NCCN TO LIFE-SAVING 2017 ANNUAL REPORT TREATMENT GUIDELINES 41

42 Improving care through ACCESS to comprehensive education In 2017, NCCN held 62 different in-person meetings and events up approximately 27% from Coupled with the continued success of the online education portal, NCCN education initiatives reached nearly 14,000 medical professionals. NCCN Annual Conference LE RW NCCN 22 nd Annual Conference: Improving the Quality, Effectiveness and Efficiency of Cancer Care tm Orlando, Florida March 23-25, 2017 Attendees: 1,656 Recorded Webcast Participants: 5,767 Held for the first time in Orlando, Florida, the NCCN 22 nd Annual Conference: Improving the Quality, Effectiveness and Efficiency of Cancer Care tm attracted more than 1,650 attendees from across the United States and the globe, including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patient with cancer. Respected opinion leaders presented the latest cancer therapies and provided updates on selected NCCN Guidelines, the data upon which the NCCN Guidelines are based, and quality initiatives in oncology. Topics focused on the major cancers and supportive care areas and included case study discussion forums with experts from NCCN Member Institutions and roundtable discussion featuring the foremost professionals from the academic, patient advocacy, government, payer, industry, and business realms. NCCN LE LW RW JO Live event Live webinar Recorded webcast Journal-based online activity SI Simulator 42

43 LE LW RW NCCN 2017 Nursing Program: Advancing Oncology Nursing tm Orlando, Florida March 22, 2017 Attendees: 186 Live Webinars: June 2-29, 2017 Webinar Participants: 1,716 Recorded Webcast Participants: 1,196 Presentations provided oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information focused on current and critical issues to provide nurses with practical information that can be implemented in the practice setting. LE RW NCCN 2017 Oncology Fellows Program: New Horizons in Quality Cancer Care tm Orlando, Florida Date: March 26, 2017 Attendees: 74 Recorded Webcast Participants: 537 Presentations educated future oncology practitioners about the application of the NCCN Guidelines and other evidence-based treatment principles in the management of significant cancer types and supportive care issues. LE RW Insights into Individualizing Treatment of Patients with Multiple Myeloma Orlando, Florida March 24, 2017 Attendees: 143 Recorded Webcast Participants: 564 This satellite symposium held in conjunction with the NCCN Annual Conference ensured that members of multidisciplinary teams, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with multiple myeloma. LE RW Examining Health Policy, Payer, Provider, and Patient Perspectives in Indolent Non-Hodgkin s Lymphoma Orlando, Florida March 24, 2017 Attendees: 146 Recorded Webcast Participants: 520 During this highly interactive satellite session, panelists and experts representing policy makers, payers, providers, and patients debated key challenges in inhl management in light of recent health policy changes, new value-based models of care delivery, and unprecedented advances in targeted therapies. Collaborative strategies for delivering quality patient-centered care and achieving the potential of inhl-related advances to optimize patient outcomes were addressed. The recorded webcast was made available through the NCCN Continuing Education Portal. NCCN 2017 ANNUAL REPORT NCCN LE LW RW JO SI Live event Live webinar Recorded webcast Journal-based online activity Simulator 43

44 NCCN Annual Congress LE RW NCCN 12 th Annual Congress: Hematologic Malignancies tm San Francisco, California Date: October 6-7, 2017 Attendees: 546 Recorded Webcast Participants: 1,201 The NCCN 12 th Annual Congress: Hematologic Malignancies tm included 16 educational sessions featuring the latest advances in patient management for hematologic malignancies, including new and updated NCCN Guidelines. Attendees also had the opportunity to attend panels focused on interesting and challenging cancer studies. LE RW NCCN 2017 Nursing Forum: Oncology Nursing in Hematologic Malignancies tm San Francisco, California Date: October 6, 2017 Attendees: 85 Recorded Webcast Participants: 231 The NCCN Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies tm held during the NCCN 12 th Annual Congress provided hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information focused on current and critical issues to provide hematology/ oncology nurses with practical information that could be implemented in the practice setting. NCCN Congress Series tm LE LW RW NCCN Congress Series tm : Breast Cancer with Updates from the 2016 San Antonio Breast Cancer Symposium Chicago, Illinois February 10, 2017 Attendees: 174 Webinar Participants: 3,171 Recorded Webcast Participants: 3,622 This live congress, with five live webinars that covered the complex strategies for screening, testing, and individualized treatment strategies for breast cancer, and included the latest updates from the 2016 San Antonio Breast Cancer Symposium. LE LW RW NCCN Congress Series tm : Lung Cancer Baltimore, Maryland July 21, 2017 Attendees: 93 Live Webinars: August - October 2017 Webinar Attendees: 1,432 Recorded Webcast Participants: 468 This live congress, with five live webinars focused on current and emerging scientific data for health care professionals to make evidence-based decisions about screening and treatment for patients with Lung Cancer. NCCN LE LW RW JO SI Live event Live webinar Recorded webcast Journal-based online activity Simulator 44

45 NCCN Congress Webinar Series tm LW RW NCCN Congress Webinar Series tm : Biomarkers 101 November - December 2017 Live Webinar Participants: 1,364 Recorded Webcasts launched Dec 2017 A series of four live webinars presented the latest advances in molecular testing, including a background on biomarker tests and their approval process, the utilization of biomarkers in clinical trials, determining appropriate biomarker utilization, and the clinical utility of biomarker testing. General Programs LE GAIN: EnGAging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment, and Treatment Tampa, Florida / Atlanta, Georgia / San Francisco, California / St. Louis, Missouri / Houston, Texas / Pittsburgh, Pennsylvania January - May 2017 Attendees: 165 A series of seven (five in 2017) regional summits were developed by NCCN, American College of Chest Physicians, the American Society of Clinical Pathology, International Association for the Study of Lung Cancer, and The France Foundation. Summits included casebased discussion and interactive simulations to address unmet needs and clinical gaps in care of patients with locally advanced and metastatic non-small cell lung cancer. NCCN LW RW Monthly Oncology Tumor Board Series tm : A Multidisciplinary Approach to Individualized Care February - December 2017 Live Webinars: 2,619 Recorded Webcast Participants: 1,823 LE LW RW JO SI Live event Live webinar Recorded webcast Journal-based online activity Simulator 45

46 Monthly case-based live webinars on a variety of cancer types taught clinicians how to best apply appropriate standard of care, including identifying circumstances where appropriate management requires adapting NCCN Guidelines to individual patient s needs. LE RW Evolving Treatment Landscape for Advanced Renal Cell Carcinoma: Combination and Sequential Strategies and Immunotherapies with The France Foundation Philadelphia, Pennsylvania / Houston, Texas / New York, New York March 2017 Attendees: Over 130 Recorded Webcast Participants: 612 A live series of three regional summits developed by NCCN and The France Foundation educated urologists, oncologists, NPs and PAs on the evolving treatment landscape for advanced renal cell carcinoma. The program also discussed combination and sequential strategies and immunotherapies. Small groups met to review challenging cases and receive valuable feedback from the faculty experts. A satellite meeting held in conjunction with the 2017 ASCO Annual Meeting discussed all the relevant data along with strategies for optimal application in specific case scenarios, is essential for clinicians to adopt biosimilars. A recorded webcast was made available through the NCCN Continuing Education Portal. LW RW NCCN Case Manager and Medical Director Program tm September - December 2017 Live Webinars: 1,986 Recorded Webcasts launched Dec 2017 These six presentations were designed to help case managers and medical directors learn more about the current state-of-the-art oncology practice and patient management according to recent recommendations in the NCCN Guidelines for a variety of cancer types and supportive care regimens. NCCN LE LW Live event Live webinar LE RW Understanding the Expanding Role of Biosimilars in Quality Cancer Care with CCO Chicago, Illinois June 3, 2017 Attendees: 186 Recorded Webcast Participants: 564 RW JO SI Recorded webcast Journal-based online activity Simulator 46

47 JO NCCN Guidelines Insights 2017: Behind the Guidelines Insights into the Standard of Care in Oncology January - December 2017 Participants: 4,977 Within each issue of JNCCN, NCCN Guidelines panel members shed light on the deliberation process behind the creation of the NCCN Guidelines, clarifying why and how these important decisions are made. These NCCN Guidelines Insights are designed to assist readers in understanding some of the issues that panel members face and the ways that they apply data to make recommendations. SI Advanced Non-Small Cell Lung Cancer Patient Management Simulator (Powered by Syandus) May Present Participants: 1,070 Participants acquired state-of-the art knowledge of NSCLC management by treating virtual patients with highly realistic presentations of NSCLC and associated conditions. Participants worked in a risk-free environment and received valuable feedback on each treatment decision they made. LE RW Expert Guidance for Optimizing Immune Checkpoint Inhibitor Therapy for Kidney and Bladder Cancer Orlando, Florida February 16, 2017 \ Attendees: 93 March 24, 2017 \ Attendees: 123 Recorded Webcast Participants: 420 This satellite meeting held in conjunction with ASCO GU 2017 presented the latest data on the use of immune checkpoint inhibitors and corresponding guideline recommendations for the optimal care of patients with renal cell carcinoma and bladder cancer. LE RW Practical Guidance on New Immuno-Oncology Strategies for Renal Cell and Urothelial Carcinoma Chicago, IL June 4, 2017 Attendees: 140 During this satellite meeting held in conjunction with ASCO Annual Meeting, expert faculty deliberated the latest evidence-based strategies for using new immunotherapies in patients with kidney and bladder cancers. NCCN LE LW RW JO Live event Live webinar Recorded webcast Journal-based online activity SI Simulator 47

48 NCCN Leading through experience. NCCN 2017 ANNUAL REPORT 2017 RODGER WINN AWARD The Rodger Winn Award is presented to a faculty member who embodies Dr. Winn s enthusiasm, love of life, and dedication and commitment to the development of evidence-based guidelines tempered by expert judgment. The award recognizes service in the development of the NCCN Guidelines program, promotion of collegiality in NCCN activities, commitment to excellence, and dedication to multidisciplinary care. James Mohler, MD, accepts the Rodger Winn Award The 2017 Rodger Winn Award was presented to James Mohler, MD, Associate Director and Senior Vice President for Translational Research, Chair of the Department of Urology, and Professor of Oncology, Roswell Park Cancer Institute. In his current role with NCCN, Dr. Mohler serves as chair of the NCCN Guidelines Panel for Prostate Cancer and as a member of the NCCN Guidelines Panel for Prostate Cancer Early Detection. Dr. Mohler also serves on the editorial board of JNCCN. NCCN NCCN BOARD OF PRODUCERS AWARD The NCCN Board of Producers Award is given to individuals who, over the past year, have exceeded expectations and provided exemplary service in helping NCCN achieve its mission through their passion to improve the care of people with cancer. The 2017 Board of Producers Award was presented to the co-chairs of the NCCN Guidelines Panel for Cervical, Uterine, and Vulvar Cancers: Benjamin Greer, MD, former Network Medical Director (retired), and Wui-Jin Koh, MD, Service Medical Director for Radiation Oncology, Seattle Cancer Care Alliance. While continuing to provide exemplary service is in the duties of NCCN Guidelines Panel co-chairs, such as Guidelines updates, NCCN Evidence Blocks tm, Compendia, chemotherapy order templates, education programs, and JNCCN, Drs. Greer and Koh pioneered the development process for the NCCN Framework tm. This process, requiring extensive travel and many pre-dawn conference calls, resulted in a new paradigm in treating locally advanced cervical cancer when radiation therapy is unavailable, which was adopted in select low-resource settings almost immediately. Drs. Greer and Koh also initiated the NCCN Guidelines for Vulvar Cancer, first published in ACCESS TO LIFE-SAVING Wui-Jin Koh, MD, accepts the Board TREATMENT GUIDELINES of Producers Award on behalf of Benjamin Greer, MD 48

49 EXECUTIVE COMMITTEE Timothy J. Eberlein, MD / Chair Jan C. Buckner, MD Rebecca L. Caires, MBA Barbara Parker, MD Lori C. Pickens, MHA Dorothy E. Puhy, MBA Samuel M. Silver, MD, PhD, MACP F. Marc Stewart, MD Jeff A. Walker, MBA Ronald S. Walters, MD, MBA, MHA, MS NCCN BOARD OF DIRECTORS Timothy J. Eberlein, MD / Chair Jan C. Buckner, MD / Vice-Chair Lori C. Pickens, MHA / Secretary Dorothy E. Puhy, MBA / Treasurer Frederick R. Appelbaum, MD Al B. Benson III, MD, FACP, FASCO Mara G. Bloom, JD, MS Julie Brabbs, MBA Laurel Bray-Hanin, MA Christopher R. Brent, MSHA Rebecca L. Caires, MBA William E. Carson III, MD Peter Connor, MS Gena Cook NCCN Foundation Board of Directors Kenneth H. Cowan, MD, PhD Thomas A. D'Amico, MD Stephen B. Edge, MD, FACS, FASCO Roswell Park David S. Ettinger, MD, FACP, FCCP Marwan G. Fakih, MD City of Hope Richard I. Fisher, MD Theresa J. Franco, MSN, RN Lauren E. Hackett, MPA Louis B. Harrison, MD Matt Kalaycio, MD Case / Mark F. Kochevar, MBA Michael R. Kuettel, MD, PhD, MBA Roswell Park Razelle Kurzrock, MD Rogerio Lilenbaum, MD Christina J. Longnecker, MBA, JD, BSN, RN Abe Lopman, MBA Cynthia McCollum, MBA Lisle M. Nabell, MD Michael N. Neuss, MD Patrick J. O'Brien, MBA Ruth M. O'Regan, MD Alberto S. Pappo, MD Barbara Parker, MD NCCN As of December 31,

50 David G. Pfister, MD Amy B. Porter-Tacoronte, MBA W. Thomas Purcell, MD, MBA Eben L. Rosenthal, MD Marty Sargeant, MBA City of Hope Lee S. Schwartzberg, MD, FACP Sridhar Seshadri, PhD Samuel M. Silver, MD, PhD, MACP Warren Smedley, MSHA F. Marc Stewart, MD John W. Sweetenham, MD, FACP, FRCP Ben Tanner, MHA Ted Teknos, MD Case / Alan P. Venook, MD Jeff A. Walker, MBA Ronald S. Walters, MD, MBA, MHA, MS Randal S. Weber, MD FINANCE COMMITTEE Dorothy E. Puhy, MBA / Chair Lauren E. Hackett, MPA Mark F. Kochevar, MBA Jeff A. Walker, MBA GOVERNANCE COMMITTEE Jan C. Buckner, MD / Chair Al B. Benson III, MD, FACP, FASCO Thomas A. D'Amico, MD Timothy J. Eberlein, MD Lori C. Pickens, MHA Dorothy E. Puhy, MBA Warren Smedley, MSHA John W. Sweetenham, MD, FACP, FRCP NCCN SENIOR MANAGEMENT TEAM Robert W. Carlson, MD Chief Executive Officer Gary J. Weyhmuller, MBA, SPHR Executive Vice President/Chief Operating Officer Lisa Kimbro, CPA, MBA Senior Vice President, Finance/Chief Finance Officer Joan S. McClure, MS Senior Vice President, Clinical Information & Publications C. Lyn Fitzgerald, MJ Senior Vice President, U.S. & Global Development Kristina M. Gregory, MSN, OCN, RN Vice President, Clinical Information Operations Linda Leach Vice President, Administration & Human Relations NCCN As of December 31,

51 BEST PRACTICES COMMITTEE F. Marc Stewart, MD / Co-Chair Warren Smedley, MSHA / Co-Chair James Bachman, MPA Mara G. Bloom, JD, MS Laurel Bray-Hanin, MA Susan J. Brown, PhD, MSN, RN, NEA-BC City of Hope Rebecca L. Caires, MBA Julie Croner, MPH Pam Dotson, BSN William Dunson, MD Theresa J. Franco, MSN, RN Anne H. Gross, PhD, RN Lauren E. Hackett, MPA Donna M. Healy, MSN, RN Shirley A. Johnson, MBA, MS, RN Roswell Park Stacey T. Jones, MBA, RN Julian Kim, MD Case / Kris Kipp, MSN, RN Timothy Kubal, MD, MBA Christina J. Longnecker, MBA, JD, BSN, RN Catherine Lyons, MS, RN, NEA-BC Cynthia McCollum, MBA Maureen K. McDade Daniel Mulkerin, MD Amy B. Porter-Tacoronte, MBA Kim Slusser, MSN, BSN Irene Turkewycz, MEd, BSN, RN Ronald S. Walters, MD, MBA, MHA, MS EDUCATIONAL PROGRAMS ADVISORY COMMITTEE Sally Barbour, PharmD, BCOP, CPP Al B. Benson III, MD, FACP, FASCO David S. Ettinger, MD, FACP, FCCP Ramaswamy Govindan, MD Brenda Shelton, DNSc, RN, AOCN Andrew D. Zelenetz, MD, PhD EHR ONCOLOGY ADVISORY GROUP Mia Levy, MD, PhD / Chair Daniel Martin, MD / Vice-Chair J. Robert Beck, MD Lynn Borstelmann, DNP, RN, NEA-BC Patrick K. Campbell, MD, PhD Lisa Edwards, MBA, CMPE G. Weldon Gilcrease, MD Richard Gray, MD Teresa Helsten, MD Carol Ann Huff, MD Aaron Logan, MD, PhD Paul Mansfield, MD, FACS P. Kelly Marcom, MD Lisle M. Nabell, MD Joel Neal, MD, PhD Randa Perkins, MD NCCN As of December 31,

52 Brad Pohlman, MD Case / Sylvia S. Richey, MD Matthew Rioth, MD, MS Jeffrey B. Smerage, MD, PhD Peter D. Stetson, MD, MA Robert C. Stillman, MA, CPHIMS, RN Keith Stockerl-Goldstein, MD Umberto Tachinardi, MD, MSc Vijay Trisal, MD City of Hope Andrew Wagner, MD, PhD Firas Wehbe, MD, PhD Everett Weiss, MD Roswell Park GUIDELINES STEERING COMMITTEE Ettinger, MD, FACP, FCCP / Chair Wallace Akerley, MD Al B. Benson III, MD, FACP, FASCO Jan C. Buckner, MD Harold J. Burstein, MD, PhD William E. Carson III, MD A. Dimitrios Colevas, MD Matthew Cooney, MD Case / Kenneth H. Cowan, MD, PhD Thomas A. D'Amico, MD Timothy J. Eberlein, MD Paul F. Engstrom, MD, FACP Marc Ernstoff, MD Roswell Park Marwan G. Fakih, MD City of Hope Louis B. Harrison, MD Susan A. Higgins, MD, MS Ephraim P. Hochberg, MD Madan Jagasia, MD Lisle M. Nabell, MD Ruth M. O'Regan, MD Barbara Parker, MD David G. Pfister, MD W. Thomas Purcell, MD, MBA Hope S. Rugo, MD Bryan J. Schneider, MD Lee S. Schwartzberg, MD, FACP F. Marc Stewart, MD Ronald S. Walters, MD, MBA, MHA, MS IRB Directors Forum Planning Committee Donald Handley, MBA, MSc, CIP Roswell Park Karen M. Hansen, BA Martha Jones, MA, CIP IRB DIRECTORS FORUM Joseph Baar, MD, PhD, FACP Case / Judith Birk, JD Roy Cambria Vijaya Chadaram, MSN, CCRP, RN Nichelle Cobb, PhD Linda M. Coleman, JD Victoria L. Cooper NCCN As of December 31,

53 Casey Cox Lisa Denney, MPH Anastasia Doherty, CIP Susan Ebert, MS, RD, CIP Emily Eldh Sharon L. Ellison, PharmD Elroy Fernandes, PhD Bruce Gordon, MD Amanda Hammond, JD City of Hope Donald Handley, MBA, MSc, CIP Roswell Park Karen M. Hansen, BA John C. Heldens, CCRP, CIP Nathalia Henry, MS, CHRC Laurie Herraiz, CCRP, RD, CIP Ann Johnson, PhD, MPH Dena A. Johnson, MEd Pamela Kwon, CCRP, CIP Alison Lakin, PhD, LLM, LLB, RN Richard Lush, PhD Anthony Magit, MD, MPP Kelly Maresh, MBA, BSN, CCRC Celia Molvin Cathleen M. Montano, JD Kathleen E. Murphy, PhD, CIP Gwenn Oki, MPH, CIP Van Andel Institute Julie Ozier, MHL, CHRC, CIP Paul Papagni, JD, CIP Holy Cross Hospital/Trinity Health System Gail Paulsen, BSN, RN, CIP Ernest Prentice, PhD Kathleen Price, MBA, RN, CIP Adam Pucci, CIP City of Hope Wanda A. Quezada, CCRP, CIP Philip Rocca, JD Michele Russell-Einhorn, JD Schulman IRB Sophia Sabina, MBA Meghan K. Scott Megan Singleton, JD, MBE, CIP Sidney Kimmel at Johns Hopkins Eileen Smith, MD City of Hope Catherine Sutherland, CIP Jeanne Velders, JD, CIP Camille Wicher, PhD, MSN, RN Roswell Park AFFILIATE FORUM Alan Howald / Co-Chair James Bachman, MPA / Co-Chair Elizabeth Abernathy, MSN, AOCNS, RN Wallace Akerley, MD Richard Barakat, MD Mara G. Bloom, JD, MS Cindy Burleson, MSN, CPON Anne Chiang, MD, PhD Jennie R. Crews, MD Patricia Dahl, MBA Thomas Daly, MBA Ann Egan Jessica Eves Karen Fields, MD David Freberg, MPA Armen Gallucci, FACHE Roswell Park NCCN As of December 31,

54 Yolanda Garces, MD Deborah Gentzen, MBA, BS Benjamin E. Greer, MD Amy Hay Heidi Hebson City of Hope Karen Kemby Elizabeth A. Liebow Mary Eileen McPhee Roswell Park Renee Muellenbach, MSN, RN Daniel Mulkerin, MD Sunita Panesar, MBA Roswell Park Koren A. Phillips, MBA Henry Pitot, MD Steven C. Plaxe, MD, FACOG, FACS Mark Radzyner, MBA, JD Eben L. Rosenthal, MD Joel Schwartz, MD Warren Smedley, MSHA Mark Sobczak, MD Timothy Spiro, MD Case / Linda Sutton, MD John W. Sweetenham, MD, FACP, FRCP Richard Taylor, DNP, ANP-BC, CRNP Deirdre Torto, MHA Cancer Center at Johns Hopkins Jeffrey VanDeusen, MD, PhD Alexander G. Von Bormann, MBA Arlinda Warren Renee Webb, MA, CCRC Catie Wiernasz, MSN NCCN AFFILIATE RESEARCH CONSORTIUM (ARC) COMMITTEE Karen Fields, MD / Co-Chair Alan Howald / Co-Chair Jennie Crews, MD Mark Kochevar, MBA Warren Smedley, MSHA Jack Hensold, MD Bozeman Deaconess Cancer Center Rodney Rocconi, MD University of South Alabama Mitchell Cancer Institute Cecilia Zapata, MPH, MS NCCN ORP INVESTIGATOR STEERING COMMITTEE Razelle Kurzrock, MD / Chair Wallace Akerley, MD Ajjai Alva, MBBS Frederick R. Appelbaum, MD Al B. Benson III, MD, FACP, FASCO Jordan D. Berlin, MD Ravi Bhatia, MD Aman Buzdar, MD, FACP William E. Carson III, MD Asher A. Chanan-Khan, MD Jeffrey Clark, MD A. Dimitrios Colevas, MD John DiPersio, MD, PhD NCCN As of December 31,

55 Marc Ernstoff, MD Roswell Park David S. Ettinger, MD, FACP, FCCP Marwan G. Fakih, MD City of Hope Jean L. Grem, MD Alan L. Ho, MD, PhD Harriet Kluger, MD Wells A. Messersmith, MD Anthony J. Olszanski, MD, RPh Lee S. Schwartzberg, MD, FACP Mikkael Sekeres, MD, MS Case / Thomas Stinchcombe, MD Daniel Sullivan, MD Anne Traynor, MD Alan P. Venook, MD POLICY ADVISORY GROUP Kerin B. Adelson, MD James O. Armitage, MD Julianna Belelieu, MSc Alan H. Bryce, MD Jennifer K. Carlson, BS Leann Chilton, MBA Thomas A. D'Amico, MD John DeMuro Christopher Friese, PhD, RN, AOCN, FAAN Madeline Grant James Helstrom, MD, MBA Orly Isaacson, MA Brian Kavanagh, MD, MPH, FASTRO Laura Krolczyk Roswell Park Anne Levine, MBA Alan E. Lichtin, MD Case / Melisa M. Lindamood, MPS Luis López, MPP City of Hope Mark Moreno Erich A. Mounce, MHA Steven C. Plaxe, MD, FACOG, FACS Matthew J. Resnick, MD, MMHC, MPH Terri Salter, MSN, MBA, RN Joseph Shrager, MD John W. Sweetenham, MD, FACP, FRCP Alan P. Venook, MD Sharon Weber, MD, FACS Scott Ziomek PRODUCTS AND SERVICES COMMITTEE Michael I. Rabin, MBA, MPA / Chair City of Hope Robert D. Auerbach, Esq. Angela Bailey, MBA Julian Bell, CPA, MHA Kim Bell, MBA, RN Case / Kimberly Brandt, MBA, BSN, OCN, RN Kara Campbell Peter Casas Fred Castellano, MBA Bernice Chrobak Thomas Daly, MBA NCCN As of December 31,

56 Cathy Eghigian Brandon Elliott, MBA, MS Marion Everidge, MHA Raheel M. Farough Andrew G. Fleming, BS Trisha M. Frick, MS, RN Claudio A. Garcia, CFA Katie Grace Madeline Grant Sonia Grizzle Sheri C. Haun, MBA Steve L. Knudson, MBA Diane P. Lanahan, MBA, RN Jill Lemke Brady M. Luby, MS Ray Lynch, CPA, MBA David W. Maberry, MHA Laura E. Mann, BA As of December 31, 2017 Lisa L. Ogorzalek, JD, MHA Aimee Olivier, MA Jennifer Ortlieb, BA Cindy Parker Mark Radzyner, MBA, JD Sara Randolph Roswell Park Jane Raymond, MBA David M. Rubin Casey (Jonathan) Sandack, MBA Mindy Scharlin, MPH Geri Schmid, BA Helene Stephan Pascale Susi Shannon Vanderbilt Zac Watne, MA Mark Zenger, MBA, MHA QUALITY AND OUTCOMES COMMITTEE Thomas A. D'Amico, MD / Chair Alan J. Balch, PhD Patient Advocate Foundation Al B. Benson III, MD, FACP, FASCO Stephen B. Edge, MD, FACS, FASCO Roswell Park Robert Green, MD Flatiron Shaji K. Kumar, MD Neal J. Meropol, MD Flatiron Health James L. Mohler, MD Roswell Park David G. Pfister, MD Ronald S. Walters, MD, MBA, MHA, MS JNCCN EDITORIAL BOARD EDITOR-IN-CHIEF Margaret Tempero, MD EXECUTIVE EDITORIAL BOARD Al B. Benson III, MD Mary B. Daly, MD, PhD Crystal S. Denlinger, MD Jimmie C. Holland, MD Andrew D. Zelenetz, MD, PhD EDITORIAL BOARD MEMBERS Jaffer A. Ajani, MD Deborah K. Armstrong, MD NCCN 56

57 Lindsey Robert Baden, MD Ann M. Berger, PhD, AOCNS, APRN Therese B. Bevers, MD Christopher K. Bichakjian, MD J. Sybil Biermann, MD Patrick A. Brown, MD Peter R. Carroll, MD, MPH Peter F. Coccia, MD Daniel G. Coit, MD Jeffrey Crawford, MD Maria Dans, MD Efrat A. Dotan, MD David S. Ettinger, MD Elliot K. Fishman, MD Thomas W. Flaig, MD Aaron T. Gerds, MD, MS Case / Timothy D. Gilligan, MD, MS Case / William J. Gradishar, MD Peter L. Greenberg, MD Robert I. Haddad, MD Richard T. Hoppe, MD Steven M. Horwitz, MD Gregory P. Kalemkerian, MD Wui-Jin Koh, MD Matthew H. Kulke, MD, MMSc Shaji K. Kumar, MD James L. Mohler, MD Roswell Park Robert J. Motzer, MD Louis Burt Nabors, MD Margaret R. O Donnell, MD City of Hope David G. Pfister, MD Dawn Provenzale, MD, MS Jerald P. Radich, MD Erin Reid, MD George M. Rodgers III, MD, PhD Peter G. Shields, MD Cancer Center James Cancer Hospital Michael B. Streiff, MD Gita Suneja, MD Robert A. Swarm, MD John A. Thompson, MD Margaret von Mehren, MD William G. Wierda, MD, PhD Douglas E. Wood, MD, FRSCEd NCCN GUIDELINES PANELS BY CANCER TYPE ACUTE LYMPHOBLASTIC LEUKEMIA Patrick A. Brown, MD / Chair Bijal Shah, MD / Vice-Chair Anjali Advani, MD Case / Patricia Aoun, MD, MPH City of Hope Stefan K. Barta, MD, MRCP, MS Bhavana Bhatnagar, DO Michael W. Boyer, MD NCCN As of December 31,

58 Teresa Bryan, MD Patrick W. Burke, MD Ryan D. Cassaday, MD Peter F. Coccia, MD Steve E. Coutre, MD Lloyd E. Damon, MD Daniel J. DeAngelo, MD, PhD Amir T. Fathi, MD Olga Frankfurt, MD John P. Greer, MD Hagop M. Kantarjian, MD Mark Litzow, MD Arthur Liu, MD, PhD Stephanie Massaro, MD Ryan J. Mattison, MD Jae Park, MD Jeffrey E. Rubnitz, MD, PhD Ayman A. Saad, MD As of December 31, 2017 Geoffrey L. Uy, MD Eunice S. Wang, MD Roswell Park Matthew Wieduwilt, MD, PhD ACUTE MYELOID LEUKEMIA Margaret R. O'Donnell, MD / Chair City of Hope Martin S. Tallman, MD / Vice-Chair Camille N. Abboud, MD Jessica K. Altman, MD Frederick R. Appelbaum, MD Vijaya Raj Bhatt, MBBS Dale Bixby, MD, PhD Steve E. Coutre, MD Marcos De Lima, MD Case / Amir T. Fathi, MD Melanie Fiorella, MD James M. Foran, MD Aric C. Hall, MD Patricia Kropf, MD Jeffrey Lancet, MD Guido Marcucci, MD City of Hope Mike G. Martin, MD Alice Mims, MD Joseph O. Moore, MD Rebecca Olin, MD Deniz Peker, MD Daniel A. Pollyea, MD, MS Keith Pratz, MD Thomas Prebet, MD, PhD Farhad Ravandi-Kashani, MD Paul J. Shami, MD Richard M. Stone, MD Stephen A. Strickland, MD, MSCI Eunice S. Wang, MD Roswell Park Matthew Wieduwilt, MD, PhD AIDS-RELATED KAPOSI SARCOMA Erin Reid, MD / Co-Chair Gita Suneja, MD / Co-Chair Richard F. Ambinder, MD, PhD NCCN 58

59 Kevin Ard, MD, MPH Robert Baiocchi, MD, PhD Stefan K. Barta, MD, MRCP, MS Evie Carchman, MD Adam Cohen, MD Neel Gupta, MD Kimberly L. Johung, MD, PhD Ann Klopp, MD, PhD Ann S. LaCasce, MD Chi Lin, MD Oxana V. Makarova-Rusher, MD Amitkumar Mehta, MD Manoj P. Menon, MD, MPH David Morgan, MD Nitya Nathwani, MD City of Hope Ariela Noy, MD Frank J. Palella, MD Lee Ratner, MD, PhD Stacey Rizza, MD Michelle A. Rudek, PhD, PharmD Jeff Taylor Patient Advocate Benjamin Tomlinson, MD Case / University Hospitals Seidman Cancer Center and Chia-Ching J. Wang, MD B-CELL LYMPHOMAS Andrew D. Zelenetz, MD, PhD / Chair Leo I. Gordon, MD / Vice-Chair Jeremy S. Abramson, MD Ranjana H. Advani, MD C. Babis Andreadis, MD, MSCE Nancy Bartlett, MD Paolo F. Caimi, MD Case / Julie E. Chang, MD Julio C. Chavez, MD Beth Christian, MD Luis E. Fayad, MD Martha J. Glenn, MD Thomas M. Habermann, MD Nancy Lee Harris, MD Francisco Hernandez-Ilizaliturri, MD Roswell Park Mark S. Kaminski, MD Christopher R. Kelsey, MD Nadia Khan, MD Susan Krivacic, MPAff Consultant Ann S. LaCasce, MD Amitkumar Mehta, MD Auayporn Nademanee, MD City of Hope Rachel Rabinovitch, MD Nishitha Reddy, MD Erin Reid, MD Kenneth Roberts, MD Stephen D. Smith, MD Erin D. Snyder, MD Lode J. Swinnen, MBChB Julie M. Vose, MD, MBA NCCN As of December 31,

60 BLADDER/PENILE CANCERS Thomas W. Flaig, MD / Chair Philippe E. Spiess, MD / Vice-Chair Neeraj Agarwal, MD Rick Bangs, MBA, PMP Patient Advocate Stephen Boorjian, MD Mark Buyyounouski, MD, MS Tracy M. Downs, MD Jason A. Efstathiou, MD, DPhil Terence Friedlander, MD Richard E. Greenberg, MD, FACS Khurshid A. Guru, MD Roswell Park Noah Hahn, MD Harry W. Herr, MD Christopher J. Hoimes, MD Case / Brant A. Inman, MD, MSc Masahito Jimbo, MD, PhD, MPH A. Karim Kader, MD, PhD, FRCSC Subodh M. Lele, MD Joshua J. Meeks, MD, PhD As of December 31, 2017 Jeff Michalski, MD, MBA Jeffrey S. Montgomery, MD, MHSA Lance C. Pagliaro, MD Sumanta K. Pal, MD City of Hope Anthony Patterson, MD Daniel Petrylak, MD Elizabeth R. Plimack, MD, MS Kamal S. Pohar, MD Michael P. Porter, MD, MS Mark A. Preston, MD Wade J. Sexton, MD Arlene O. Siefker-Radtke, MD Jonathan Tward, MD, PhD Geoffrey Wile, MD BONE CANCER J. Sybil Biermann, MD / Chair Warren Chow, MD, FACP / Vice-Chair City of Hope Douglas R. Adkins, MD Mark Agulnik, MD Robert S. Benjamin, MD Brian Brigman, MD, PhD G. Thomas Budd, MD Case / Lee Cranmer, MD, PhD Aarati Didwania, MD, MSCI Nicola Fabbri, MD Margo L. Hoover-Regan, MD Joseph B. Kuechle, MD, PhD Roswell Park Dieter Lindskog, MD David R. Lucas, MD Joel Mayerson, MD Sean V. McGarry, MD Lynn Million, MD Carol D. Morris, MD, MS Sujana Movva, MD Richard O'Donnell, MD R. Lor Randall, MD, FACS Damon R. Reed, MD Peter S. Rose, MD NCCN 60

61 Victor M. Santana, MD Robert L. Satcher, MD, PhD Joseph Schwab, MD, MS Herbert Schwartz, MD Herrick J. Siegel, MD Katherine Thornton, MD Victor Villalobos, MD, PhD BREAST CANCER William J. Gradishar, MD / Chair Benjamin O. Anderson, MD / Vice-Chair Ron Balassanian, MD Sarah L. Blair, MD Harold J. Burstein, MD, PhD Amy E. Cyr, MD Anthony D. Elias, MD William B. Farrar, MD Andres Forero, MD Sharon H. Giordano, MD, MPH Matthew P. Goetz, MD Lori J. Goldstein, MD Steven J. Isakoff, MD, PhD Janice Lyons, MD Case / P. Kelly Marcom, MD Ingrid A. Mayer, MD, MSCI Beryl McCormick, MD Meena S. Moran, MD Ruth M. O'Regan, MD Sameer A. Patel, MD, FACS Lori J. Pierce, MD Elizabeth C. Reed, MD Kilian E. Salerno, MD Roswell Park Lee S. Schwartzberg, MD, FACP Amy Sitapati, MD Karen Lisa Smith, MD, MPH Mary Lou Smith, JD, MBA Patient Advocate Hatem Soliman, MD George Somlo, MD City of Hope Melinda L. Telli, MD John H. Ward, MD CENTRAL NERVOUS SYSTEM CANCERS Louis B. Nabors, MD / Chair Jana Portnow, MD / Vice-Chair City of Hope Joachim Baehring, MD Henry Brem, MD Nicholas Butowski, MD Peter Forsyth, MD Jona Hattangadi-Gluth, MD Matthias Holdhoff, MD, PhD Craig Horbinski, MD, PhD Steven Howard, MD Larry Junck, MD Thomas Kaley, MD Priya Kumthekar, MD Jay S. Loeffler, MD NCCN As of December 31,

62 Paul Moots, MD Maciej M. Mrugala, MD, PhD, MPH Seema Nagpal, MD Manjari Pandey, MD Ian Parney, MD, PhD Katherine Peters, MD, PhD Dheerendra Prasad, MD, FACRO Roswell Park Vinay K. Puduvalli, MD John W. Ragsdale III, MD Jason Rockhill, MD, PhD Lisa Rogers, DO Case / Chad Rusthoven, MD Nicole Shonka, MD Dennis C. Shrieve, MD, PhD Allen K. Sills, MD Lode J. Swinnen, MBChB Christina Tsien, MD Stephanie Weiss, MD Patrick Yang Wen, MD Nicole Willmarth, PhD Patient Advocate CERVICAL/UTERINE/VULVAR CANCERS Wui-Jin Koh, MD / Chair Nadeem Abu-Rustum, MD / Vice-Chair Sarah M. Bean, MD Kristin Bradley, MD Susana M. Campos, MD, MPH, MS Kathleen R. Cho, MD Hye Sook Chon, MD Christina S. Chu, MD David Cohn, MD Marta Crispens, MD Shari Damast, MD Oliver Dorigo, MD, PhD Patricia J. Eifel, MD Christine M. Fisher, MD, MPH Peter Frederick, MD Roswell Park David K. Gaffney, MD, PhD Suzanne George, MD Ernest Han, MD, PhD City of Hope Warner K. Huh, MD John R. Lurain, MD Andrea Mariani, MD David G. Mutch, MD Christa I. Nagel, MD Case / Larissa Nekhlyudov, MD, MPH Amanda Nickles Fader, MD Steven W. Remmenga, MD R. Kevin Reynolds, MD Todd D. Tillmanns, MD Stefanie Ueda, MD Emily A. Wyse Patient Advocate Catheryn M. Yashar, MD NCCN As of December 31,

63 CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA/HAIRY CELL LEUKEMIA William G. Wierda, MD, PhD / Chair John C. Byrd, MD / Vice-Chair Jeremy S. Abramson, MD Syed F. Bilgrami, MD Greg Bociek, MD, MSc Danielle Brander, MD Jennifer R. Brown, MD, PhD Asher A. Chanan-Khan, MD Steve E. Coutre, MD Randall S. Davis, MD Christopher D. Fletcher, MD Brian Hill, MD, PhD Case / Brad S. Kahl, MD Manali Kamdar, MD Lawrence D. Kaplan, MD Nadia Khan, MD Thomas J. Kipps, MD, PhD Jeffrey Lancet, MD Shuo Ma, MD, PhD Sami Malek, MD Claudio Mosse, MD, PhD Mazyar Shadman, MD, MPH Tanya Siddiqi, MD City of Hope Deborah Stephens, DO Nina Wagner, MD Andrew D. Zelenetz, MD, PhD CHRONIC MYELOID LEUKEMIA Jerald P. Radich, MD / Chair Michael W. Deininger, MD, PhD / Vice-Chair Camille N. Abboud, MD Jessica K. Altman, MD Ellin Berman, MD Ravi Bhatia, MD Bhavana Bhatnagar, DO Peter Curtin, MD Daniel J. DeAngelo, MD, PhD Jason Gotlib, MD, MS Gabriela Hobbs, MD Madan Jagasia, MD Hagop M. Kantarjian, MD Lori J. Maness, MD Leland Metheny, MD Case / Joseph O. Moore, MD Arnel M. Pallera, MD Philip Pancari, MD Enkhtsetseg Purev, MD, PhD Michal G. Rose, MD Neil P. Shah, MD, PhD B. Douglas Smith, MD David S. Snyder, MD City of Hope Kendra L. Sweet, MD, MS NCCN As of December 31,

64 Moshe Talpaz, MD James Thompson, MD Roswell Park David T. Yang, MD COLON/RECTAL/ANAL CANCERS Al B. Benson III, MD, FACP, FASCO / Chair Alan P. Venook, MD / Vice-Chair Lynette Cederquist, MD Yi-Jen Chen, MD, PhD City of Hope Kristen K. Ciombor, MD Stacey Cohen, MD Harry S. Cooper, MD Dustin Deming, MD Paul F. Engstrom, MD, FACP Ignacio Garrido-Laguna, MD, PhD Jean L. Grem, MD Axel Grothey, MD Howard S. Hochster, MD Sarah Hoffe, MD Steven Hunt, MD Ahmed Kamel, MD As of December 31, 2017 Natalie Kirilcuk, MD Smitha Krishnamurthi, MD Case / Wells A. Messersmith, MD Jeffrey Meyerhardt, MD, MPH Eric D. Miller, MD, PhD Mary F. Mulcahy, MD James D. Murphy, MD, MS Steven Nurkin, MD, MS Roswell Park Leonard Saltz, MD David Shibata, MD John M. Skibber, MD Constantinos T. Sofocleous, MD, PhD, FCIRSE, FSIR Elena M. Stoffel, MD, MPH Eden Stotsky-Himelfarb, BSN, RN Christopher G. Willett, MD ESOPHAGEAL/GASTRIC CANCERS Jaffer A. Ajani, MD / Chair Thomas A. D'Amico, MD / Vice-Chair Maria Q. Baggstrom, MD, FACP David J. Bentrem, MD, MS Joseph Chao, MD City of Hope Prajnan Das, MD, MPH, MS Crystal S. Denlinger, MD, FACP Peter C. Enzinger, MD Paul Fanta, MD Farhood Farjah, MD Hans Gerdes, MD Robert E. Glasgow, MD James A. Hayman, MD, MBA Steven Hochwald, MD Roswell Park Wayne L. Hofstetter, MD David H. Ilson, MD, PhD Dawn Jaroszewski, MD Kimberly L. Johung, MD, PhD Rajesh N. Keswani, MD Lawrence R. Kleinberg, MD NCCN 64

65 Stephen Leong, MD Catherine Linn, MD Quan P. Ly, MD Kristina A. Matkowskyj, MD, PhD Mary F. Mulcahy, MD Ravi K. Paluri, MD, MPH, FACP Kyle A. Perry, MD Jose M. Pimiento, MD George A. Poultsides, MD, MS, FACS Vivian E. Strong, MD Mary Kay Washington, MD, PhD Benny Weksler, MD, MBA, FACS Georgia L. Wiesner, MD Christopher G. Willett, MD Cameron D. Wright, MD HEAD AND NECK CANCERS David G. Pfister, MD / Chair Sharon Spencer, MD / Vice-Chair David Adelstein, MD Case / Douglas R. Adkins, MD David M. Brizel, MD Barbara Burtness, MD Paul M. Busse, MD, PhD Jimmy J. Caudell, MD, PhD Anthony Cmelak, MD A. Dimitrios Colevas, MD David W. Eisele, MD, FACS Moon Fenton, MD, PhD Robert L. Foote, MD, FACR Jill Gilbert, MD Maura L. Gillison, MD, PhD Robert I. Haddad, MD Wesley L. Hicks, Jr., MD Roswell Park Ying J. Hitchcock, MD Antonio Jimeno, MD, PhD Debra S. Leizman, MD Case / Ellie Maghami, MD City of Hope Loren K. Mell, MD Bharat B. Mittal, MD Harlan A. Pinto, MD John A. Ridge, MD, PhD, FACS James W. Rocco, MD, PhD Cristina P. Rodriguez, MD Jatin P. Shah, MD, PhD Randal S. Weber, MD Matthew E. Witek, MD, MS Francis Worden, MD Sue S. Yom, MD, PhD, MAS Weining Zhen, MD HEPATOBILIARY CANCERS Al B. Benson III, MD, FACP, FASCO / Chair Michael I. D'Angelica, MD / Vice-Chair Daniel E. Abbott, MD Thomas A. Abrams, MD Steven R. Alberts, MD, MPH Daniel A. Anaya, MD NCCN As of December 31,

66 Chandrakanth Are, MD, MBBS, MBA, FACS, FRCS Daniel B. Brown, MD, FSIR Daniel T. Chang, MD Anne M. Covey, MD William G. Hawkins, MD Renuka Iyer, MD Roswell Park Rojymon Jacob, MD Andreas Karachristos, MD R. Kate Kelley, MD Robin Kim, MD Manisha Palta, MD James O. Park, MD Vaibhav Sahai, MD, MS Tracey Schefter, MD Carl R. Schmidt, MD, FACS Jason K. Sicklick, MD Gagandeep Singh, MD City of Hope Davendra Sohal, MD, MPH Case / Stacey M. Stein, MD G. Gary Tian, MD, PhD, FACP Jean-Nicolas Vauthey, MD Alan P. Venook, MD Andrew X. Zhu, MD, PhD HODGKIN LYMPHOMA Richard T. Hoppe, MD / Chair Ranjana H. Advani, MD / Vice-Chair Weiyun Z. Ai, MD, PhD Richard F. Ambinder, MD, PhD Patricia Aoun, MD, MPH City of Hope Philippe Armand, MD, PhD Celeste M. Bello, MD, MSPH Cecil M. Benitez, PhD Philip J. Bierman, MD Robert Chen, MD City of Hope Bouthaina Dabaja, MD Robert Dean, MD Case / Andres Forero, MD Leo I. Gordon, MD Francisco J. Hernandez-Ilizaliturri, MD Roswell Park Ephraim P. Hochberg, MD Jiayi Huang, MD Patrick B. Johnston, MD, PhD Mark S. Kaminski, MD Vaishalee P. Kenkre, MD Nadia Khan, MD Kami Maddocks, MD David G. Maloney, MD, PhD Monika Metzger, MD Joseph O. Moore, MD David Morgan, MD Craig H. Moskowitz, MD Carolyn Mulroney, MD Rachel Rabinovitch, MD Stuart Seropian, MD Randa Tao, MD NCCN As of December 31,

67 Jane N. Winter, MD Joachim Yahalom, MD KIDNEY CANCER Robert J. Motzer, MD / Chair Eric Jonasch, MD / Vice-Chair Neeraj Agarwal, MD Sam Bhayani, MD William Bro, BS Patient Advocate Sam S. Chang, MD Toni K. Choueiri, MD Brian A. Costello, MD, MS Ithaar H. Derweesh, MD Rodney Ellis, MD Case / Mayer Fishman, MD, PhD Thomas H. Gallagher, MD Saby George, MD, FACP Roswell Park John L. Gore, MD, MS Steven L. Hancock, MD Michael Harrison, MD Won Kim, MD Christos Kyriakopoulos, MD Chad Lagrange, MD, FACS Elaine T. Lam, MD Clayton Lau, MD City of Hope Andrew McDonald, MD, MS M. Dror Michaelson, MD, PhD Thomas Olencki, DO Phillip M. Pierorazio, MD Elizabeth R. Plimack, MD, MS Bruce G. Redman, DO Brian Shuch, MD Bradley G. Somer, MD Jeffrey A. Sosman, MD MELANOMA Daniel G. Coit, MD, FACS / Chair John A. Thompson, MD / Vice-Chair Mark R. Albertini, MD Alain P. Algazi, MD Robert H. Andtbacka, MD Christopher A. Barker, MD Christopher K. Bichakjian, MD William E. Carson III, MD Gregory A. Daniels, MD, PhD Dominick DiMaio, MD Ryan C. Fields, MD Martin D. Fleming, MD, FACS Anjela Galan, MD Brian Gastman, MD Case / Rene Gonzalez, MD Valerie Guild, MBA Patient Advocate Douglas Johnson, MD, MSCI Richard W. Joseph, MD Julie R. Lange, MD, ScM Kim A. Margolin, MD City of Hope Miguel A. Materin, MD Sameer Nath, MD NCCN As of December 31,

68 Anthony J. Olszanski, MD, RPh Patrick Ott, MD, PhD Aparna Priyanath Gupta, MD Kumar Rao, MD Ramesh Rengan Merrick I. Ross, MD April K. Salama, MD Joseph Skitzki, MD Roswell Park Jeffrey A. Sosman, MD Susan M. Swetter, MD Kenneth K. Tanabe, MD Marshall M. Urist, MD Evan Wuthrick, MD MULTIPLE MYELOMA/ SYSTEMIC LIGHT CHAIN AMYLOIDOSIS/WALDENSTRÖM'S MACROGLOBULINEMIA Shaji K. Kumar, MD / Chair Natalie S. Callander, MD / Vice-Chair Melissa Alsina, MD Djordje Atanackovic, MD J. Sybil Biermann, MD Jorge Castillo, MD Jason C. Chandler, MD Caitlin Costello, MD Matthew Faiman, MD, MBA, FACP Case / Henry C. Fung, MD, FACP, FRCP Kelly Godby, MD Craig Hofmeister, MD, MPH Leona A. Holmberg, MD, PhD Sarah A. Holstein, MD, PhD Carol Ann Huff, MD Yubin Kang, MD Adetola Kassim, MD, MS Michaela Liedtke, MD Ehsan Malek, MD Case / Thomas Martin, MD Vishala T. Neppalli, MD Roswell Park James L. Omel, MD Patient Advocate Noopur Raje, MD Seema Singhal, MD George Somlo, MD City of Hope Keith Stockerl-Goldstein, MD Donna M. Weber, MD Joachim Yahalom, MD MYELODYSPLASTIC SYNDROMES Peter L. Greenberg, MD / Chair Richard M. Stone, MD / Vice-Chair Aref Al-Kali, MD John M. Bennett, MD Consultant Andrew M. Brunner, MD Hetty Carraway, MD, MBA Case / Peter Curtin, MD Carlos M. De Castro, MD NCCN As of December 31,

69 H. Joachim Deeg, MD Amy E. DeZern, MD, MHS Olga Frankfurt, MD Karin Gaensler, MD Guillermo Garcia-Manero, MD Elizabeth A. Griffiths, MD Roswell Park David Head, MD Ruth Horsfall, PhD, MS Patient Advocate Robert A. Johnson, MD, FACP Mark Juckett, MD Virginia M. Klimek, MD Rami Komrokji, MD Patricia Kropf, MD Qing Li, MD, PhD Lori J. Maness, MD Margaret R. O'Donnell, MD City of Hope Daniel A. Pollyea, MD, MS Vishnu V. Reddy, MD Paul J. Shami, MD Alison R. Walker, MD Peter Westervelt, MD, PhD Amer Zeidan, MBBS, MHS MYELOPROLIFERATIVE NEOPLASMS Aaron T. Gerds, MD, MS / Chair Case / Catriona Jamieson, MD, PhD / Vice-Chair Maria C. Castells, MD, PhD Michael W. Deininger, MD, PhD Ivana Gojo, MD Jason Gotlib, MD, MS Krishna Gundabolu, MBBS Gabriela Hobbs, MD Brandon McMahon, MD Sanjay R. Mohan, MD Stephen Oh, MD, PhD Eric Padron, MD Philip Pancari, MD Nikolaos Papadantonakis, MD, PhD Animesh Pardanani, MD, PhD Nikolai Podoltsev, MD, PhD Raajit Rampal, MD, PhD Erik Ranheim, MD, PhD Lindsay A. M. Rein, MD Bart Scott, MD, MS David S. Snyder, MD City of Hope Brady L. Stein, MD, MHS Moshe Talpaz, MD Srdan Verstovsek, MD, PhD Martha Wadleigh, MD Eunice S. Wang, MD Roswell Park NEUROENDOCRINE TUMORS Matthew H. Kulke, MD, MMSc / Chair Manisha H. Shah, MD / Vice-Chair Al B. Benson III, MD, FACP, FASCO NCCN As of December 31,

70 Emily Bergsland, MD Jordan D. Berlin, MD Lawrence S. Blaszkowsky, MD Jennifer Eads, MD Case / Paul F. Engstrom, MD, FACP Paul Fanta, MD Thomas J. Giordano, MD, PhD Whitney S. Goldner, MD John Grecula, MD Thorvardur Halfdanarson, MD Daniel Halperin, MD Jin He, MD, PhD Martin J. Heslin, MD Gregory P. Kalemkerian, MD Fouad Kandeel, MD, PhD City of Hope Sajid A. Khan, MD Pamela L. Kunz, MD Boris W. Kuvshinoff, MD, MBA Roswell Park Christopher H. Lieu, MD Robert E. Merritt, MD Venu G. Pillarisetty, MD Leonard Saltz, MD Julie Ann Sosa, MD Jonathan R. Strosberg, MD Craig R. Sussman, MD Nataliya Uboha, MD, PhD Jonathan Whisenant NON-MELANOMA SKIN CANCER Christopher K. Bichakjian, MD / Chair Thomas Olencki, DO / Vice-Chair Sumaira Z. Aasi, MD Murad Alam, MD, MBA, MSCI James S. Andersen, MD City of Hope Rachel Blitzblau, MD, PhD Glen M. Bowen, MD Carlo M. Contreras, MD Mackenzie Daly, MD Gregory A. Daniels, MD, PhD Roy Decker, MD, PhD Dominick DiMaio, MD Jeffrey M. Farma, MD Kris Fisher, MD Brian Gastman, MD Case / Karthik Ghosh, MD Roy C. Grekin, MD Kenneth Grossmann, MD, PhD Alan L. Ho, MD, PhD Karl D. Lewis, MD Manisha J. Loss, MD Jane Messina, MD Kishwer S. Nehal, MD Paul Nghiem, MD, PhD Igor Puzanov, MD, MSCI, FACP Roswell Park Chrysalyne Schmults, MD Ashok R. Shaha, MD Valencia Thomas, MD NCCN As of December 31,

71 Yaohui G. Xu, MD, PhD John A. Zic, MD NON-SMALL CELL LUNG CANCER/MALIGNANT PLEURAL MESOTHELIOMA/THYMOMAS AND THYMIC CARCINOMAS David S. Ettinger, MD, FACP, FCCP / Chair Douglas E. Wood, MD, FACS, FRCSEd / Vice-Chair Dara L. Aisner, MD, PhD Wallace Akerley, MD Jessica R. Bauman, MD Joe Y. Chang, MD, PhD Lucian R. Chirieac, MD Thomas A. D'Amico, MD Malcolm M. DeCamp, MD Thomas J. Dilling, MD, MS Michael Dobelbower, MD, PhD Ramaswamy Govindan, MD Matthew A. Gubens, MD, MS Mark Hennon, MD Roswell Park Leora Horn, MD, MSc, FRCPC Rudy P. Lackner, MD Michael Lanuti, MD Ticiana A. Leal, MD Leah J. Leisch, MD Rogerio Lilenbaum, MD Jules Lin, MD, FACS Billy W. Loo, MD, PhD Renato G. Martins, MD, MPH Gregory A. Otterson, MD Karen Reckamp, MD, MS City of Hope Gregory J. Riely, MD, PhD Steven E. Schild, MD Theresa A. Shapiro, MD, PhD James Stevenson, MD Case / Scott Swanson, MD Kurt Tauer, MD, FACP Stephen C. Yang, MD OCCULT PRIMARY David S. Ettinger, MD, FACP, FCCP / Chair Gauri R. Varadhachary, MD / Vice-Chair Daniel W. Bowles, MD Sunandana Chandra, MD, MS Mihaela Cristea, MD City of Hope Jeremiah Deneve, DO Mihaela Druta, MD Keith D. Eaton, MD, PhD David Gierada, MD G. Weldon Gilcrease, MD Kelly Godby, MD Angela Jain, MD Christina Kong, MD Jeremy Kortmansky, MD Renato Lenzi, MD Sam Lubner, MD NCCN As of December 31,

72 Martin C. Mahoney, MD, PhD Roswell Park John Phay, MD Asif Rashid, MD Kerry Reynolds, MD Leonard Saltz, MD Richard B. Schwab, MD Marc Shapiro, MD Case / Chanjuan Shi, MD, PhD Jeffrey B. Smerage, MD, PhD Marvaretta M. Stevenson, MD Harry H. Yoon, MD Matthew B. Yurgelun, MD Weining (Ken) Zhen, MD OVARIAN CANCER Deborah K. Armstrong, MD / Chair Steven C. Plaxe, MD, FACOG, FACS / Vice-Chair Ronald D. Alvarez, MD Jamie N. Bakkum-Gamez, MD Lisa M. Barroilhet, MD Kian Behbakht, MD Lee-May Chen, MD Mihaela Cristea, MD City of Hope Marie T. DeRosa, RN Patient Advocate Adam C. ElNaggar, MD David M. Gershenson, MD Heidi J. Gray, MD Ardeshir Hakam, MD Carolyn Johnston, MD Monica B. Jones, MD Charles A. Leath III, MD, MSPH Shashikant Lele, MD Roswell Park Lainie Martin, MD Ursula A. Matulonis, MD David M. O'Malley, MD Richard T. Penson, MD, MRCP Sanja Percac-Lima, MD, PhD Matthew A. Powell, MD Elena Ratner, MD Steven W. Remmenga, MD Peter G. Rose, MD Case / Paul Sabbatini, MD Shohreh Shahabi, MD Theresa L. Werner, MD PANCREATIC ADENOCARCINOMA Margaret A. Tempero, MD / Chair Mokenge P. Malafa, MD, FACS / Vice-Chair Mahmoud M. Al-Hawary, MD Horacio J. Asbun, MD Andrew Bain, MD Roswell Park Stephen W. Behrman, MD Al B. Benson III, MD, FACP, FASCO Ellen Binder, MD Dana B. Cardin, MD Charles Cha, MD NCCN As of December 31,

73 E. Gabriela Chiorean, MD Vincent Chung, MD City of Hope Brian Czito, MD Mary Dillhoff, MD Efrat Dotan, MD Cristina R. Ferrone, MD George Fisher, MD, PhD Jeffrey Hardacre, MD Case / William G. Hawkins, MD Andrew H. Ko, MD Srinadh Komanduri, MD Noelle LoConte, MD Andrew M. Lowy, MD Cassadie Moravek, BS Patient Advocate Eric K. Nakakura, MD Amol K. Narang, MD Jorge Obando, MD Eileen M. O'Reilly, MD Sushanth Reddy, MD Courtney Scaife, MD Sarah P. Thayer, MD, PhD Robert A. Wolff, MD Brian M. Wolpin, MD, MPH PROSTATE CANCER James L. Mohler, MD / Chair Roswell Park Richard J. Lee, MD, PhD / Vice-Chair Emmanuel S. Antonarakis, MD Andrew J. Armstrong, MD, ScM Anthony D'Amico, MD, PhD Brian J. Davis, MD, PhD James A. Eastham, MD Rodney Ellis, MD Case / Charles A. Enke, MD Thomas A. Farrington, BSEE Patient Advocate Celestia S. Higano, MD, FACP Eric Mark Horwitz, MD Michael Hurwitz, MD, PhD Joseph E. Ippolito, MD, PhD Christopher J. Kane, MD, FACS Michael R. Kuettel, MD, PhD, MBA Roswell Park Joshua M. Lang, MD George Netto, MD David F. Penson, MD, MPH Elizabeth R. Plimack, MD, MS Julio M. Pow-Sang, MD Thomas J. Pugh, MD Sylvia S. Richey, MD Mack Roach III, MD Stan Rosenfeld Patient Advocate Edward Schaeffer, MD, PhD Ahmad Shabsigh, MD Ted Skolarus, MD, MPH Eric J. Small, MD Sandy Srinivas, MD Jonathan Tward, MD, PhD NCCN As of December 31,

74 Przemyslaw Twardowski, MD City of Hope SMALL CELL LUNG CANCER Gregory P. Kalemkerian, MD / Chair Billy W. Loo, MD, PhD / Vice-Chair Wallace Akerley, MD Albert Attia, MD Michael Bassetti, MD Yanis Boumber, MD, PhD Roy Decker, MD, PhD Michael Dobelbower, MD, PhD Afshin Dowlati, MD Case / Robert J. Downey, MD Charles Florsheim, JD Patient Advocate Apar Kishor P. Ganti, MD John Grecula, MD Matthew A. Gubens, MD, MS Christine L. Hann, MD, PhD Jim A. Hayman, MD, MBA Rebecca Suk Heist, MD, MPH Marianna Koczywas, MD City of Hope Robert E. Merritt, MD Nisha A. Mohindra, MD Julian Molina, MD, PhD Cesar A. Moran, MD Daniel Morgensztern, MD Saraswati Pokharel, MD Roswell Park David C. Portnoy, MD Deborah J. Rhodes, MD Chad Rusthoven, MD Jacob Sands, MD Rafael Santana-Davila, MD Charles C. Williams, MD SOFT TISSUE SARCOMA Margaret Von Mehren, MD / Chair R. Lor Randall, MD, FACS / Vice-Chair Robert S. Benjamin, MD Sarah Boles, MD Marilyn M. Bui, MD, PhD Kristen N. Ganjoo, MD Suzanne George, MD Ricardo J. Gonzalez, MD Martin J. Heslin, MD John M. Kane III, MD Roswell Park Vicki Keedy, MD, MSCI Edward Kim, MD Henry Koon, MD Case / Joel Mayerson, MD Martin McCarter, MD Sean V. McGarry, MD Christian Meyer, MD, PhD Zachary S. Morris, MD, PhD Richard O'Donnell, MD Alberto S. Pappo, MD NCCN As of December 31,

75 I. Benjamin Paz, MD City of Hope Ivy A. Petersen, MD John D. Pfeifer, MD, PhD Richard F. Riedel, MD Bernice Ruo, MD Scott Schuetze, MD, PhD William D. Tap, MD Jeffrey D. Wayne, MD T-CELL/PRIMARY CUTANEOUS B-CELL LYMPHOMAS Steven Horwitz, MD / Chair Stephen Ansell, MD, PhD / Vice-Chair Weiyun Z. Ai, MD, PhD Jeffrey Barnes, MD Stefan K. Barta, MD, MRCP, MS Michael Choi, MD Mark W. Clemens, MD Ahmet Dogan, MD, PhD Francine M. Foss, MD John P. Greer, MD Ahmad Halwani, MD Bradley M. Haverkos, MD, MPH, MS Richard T. Hoppe, MD Eric Jacobsen, MD Deepa Jagadeesh, MD, MPH Case / Youn H. Kim, MD Matthew Lunning, DO Amitkumar Mehta, MD Neha Mehta-Shah, MD Yahurio Oki, MD Elise A. Olsen, MD Barbara Pro, MD Saurabh A. Rajguru, MD Satish Shanbhag, MBBS, MPH Andrei Shustov, MD Lubomir Sokol, MD, PhD Pallawi Torka, MD Roswell Park Ryan Wilcox, MD, PhD Basem M. William, MD, FACP Jasmine Zain, MD City of Hope TESTICULAR CANCER Timothy D. Gilligan, MD, MS / Chair Case / David D. Chism, MD, MS Nicholas G. Cost, MD Ithaar H. Derweesh, MD Hamid Emamekhoo, MD Darren R. Feldman, MD Daniel M. Geynisman, MD Steven L. Hancock, MD Chad Lagrange, MD, FACS Ellis G. Levine, MD Roswell Park Daniel W. Lin, MD William Lowrance, MD, MPH Paul Monk, MD Joel Picus, MD Phillip Pierorazio, MD Edward N. Rampersaud, MD NCCN As of December 31,

76 Charles J. Ryan, MD Philip Saylor, MD Kanishka Sircar, MD Katherine Tzou, MD Daniel Vaena, MD Alon Z. Weizer, MD, MS Kosj Yamoah, MD, PhD Jonathan Yamzon, MD City of Hope James Yu, MD, MHS THYROID CARCINOMA Robert I. Haddad, MD / Chair Christian Nasr, MD / Vice-Chair Case / Lindsay A. Bischoff, MD Naifa Busaidy, MD, FACP David Byrd, MD Glenda Callender, MD, FACS Paxton Dickson, MD Quan-Yang Duh, MD Hormoz Ehya, MD Whitney S. Goldner, MD Megan Haymart, MD Carl K. Hoh, MD Jason P. Hunt, MD Andrei Iagaru, MD Fouad Kandeel, MD, PhD City of Hope Peter Kopp, MD Dominick M. Lamonica, MD Roswell Park Bryan McIver, MD, PhD Christopher D. Raeburn, MD John A. Ridge, MD, PhD, FACS Matthew Ringel, MD Randall P. Scheri, MD Jatin P. Shah, MD, PhD Rebecca S. Sippel, MD Robert C. Smallridge, MD Cord Sturgeon, MD Thomas N. Wang, MD, PhD Lori J. Wirth, MD DETECTION, PREVENTION, & RISK REDUCTION BREAST CANCER RISK REDUCTION Therese B. Bevers, MD / Chair John H. Ward, MD / Vice-Chair Banu K. Arun, MD Graham A. Colditz, MD, DrPH, FAFPHM Kenneth H. Cowan, MD, PhD Mary B. Daly, MD, PhD, FACP Judy E. Garber, MD, MPH Mary L. Gemignani, MD William J. Gradishar, MD Erin Hofstatter, MD Shelley Hwang, MD, MPH Judith A. Jordan, BS M.D. Anderson Cancer Center Nicole Kounalakis, MD NCCN As of December 31,

77 Allison Kurian, MD, MSc Loretta S. Loftus, MD, MBA Martin C. Mahoney, MD, PhD Roswell Park Sofia D. Merajver, MD, PhD Ingrid Meszoely, MD Joanne Mortimer, MD, FACP City of Hope Catherine C. Parker, MD Holly Pederson, MD Case / Frances Pritchard, MD Sandhya Pruthi, MD Sagar Sardesai, MD Michelle C. Specht, MD Kala Visvanathan, MD, MHS Anne Wallace, MD, FACS Lee G. Wilke, MD Rachel Yung, MD BREAST CANCER SCREENING AND DIAGNOSIS Therese B. Bevers, MD / Chair Mark Helvie, MD / Vice-Chair Ermelinda Bonaccio, MD Roswell Park Kristine E. Calhoun, MD Mary B. Daly, MD, PhD, FACP Constance Dobbins Lehman, MD, PhD William B. Farrar, MD Judy E. Garber, MD, MPH Richard Gray, MD Caprice C. Greenberg, MD, MPH Rachel Greenup, MD, MPH Nora M. Hansen, MD Randall E. Harris, MD, PhD Alexandra S. Heerdt, MD Teresa Helsten, MD Linda Hodgkiss, MD Tamarya L. Hoyt, MD John G. Huff, MD Lisa Jacobs, MD Barbara Monsees, MD Bethany L. Niell, MD, PhD Catherine C. Parker, MD Mark Pearlman, MD Liane Philpotts, MD Laura B. Shepardson, MD Case / Mary Lou Smith, MBA, JD Patient Advocate Matthew Stein, MD Lusine Tumyan, MD City of Hope Cheryl Williams, MD GENETIC/FAMILIAL HIGH-RISK ASSESSMENT: BREAST AND OVARIAN Mary B. Daly, MD, PhD, FACP / Chair Robert Pilarski, MS, CGC / Vice-Chair NCCN As of December 31,

78 Michael P. Berry, MD, FACS Saundra S. Buys, MD Meagan Farmer, CGC Susan Friedman, DVM Patient Advocate Judy E. Garber, MD, MPH Mollie Hutton, MS, CGC Roswell Park Noah D. Kauff, MD Seema Khan, MD Catherine Klein, MD Wendy Kohlmann, MS, CGC Allison Kurian, MD, MSc Christine Laronga, MD, FACS Jennifer K. Litton, MD Lisa Madlensky, PhD, CGC Julie S. Mak, MS Sofia D. Merajver, MD, PhD Kenneth Offit, MD Tuya Pal, MD Gwen Reiser, MS, CGC Kristen Mahoney Shannon, MS, CGC Elizabeth Swisher, MD Premal Thaker, MD Shaveta Vinayak, MD Case / Jeffrey N. Weitzel, MD City of Hope Myra J. Wick, MD, PhD Kari Wisinski, MD GENETIC: COLORECTAL/ COLORECTAL CANCER SCREENING Dawn Provenzale, MD, MS / Chair Samir Gupta, MD / Vice-Chair Dennis J. Ahnen, MD Amie Blanco, MS, CGC Travis H. Bray, PhD Patient Advocate Daniel C. Chung, MD Gregory Cooper, MD Case / Dayna S. Early, MD James M. Ford, MD Francis M. Giardiello, MD, MBA William M. Grady, MD Michael Hall, MD, MS Amy Halverson, MD Stanley R. Hamilton, MD Heather Hampel, MS, CGC Priyanka Kanth, MD Jason B. Klapman, MD David W. Larson, MD Audrey J. Lazenby, MD Xavier Llor, MD, PhD Patrick M. Lynch, MD, JD Arnold Markowitz, MD Robert J. Mayer, MD June Mikkelson, MS, CGC Roswell Park Reid M. Ness, MD, MPH Scott E. Regenbogen, MD, MPH Thomas P. Slavin, MD City of Hope NCCN As of December 31,

79 Shajanpeter Sugandha, MD Jennifer M. Weiss, MD, MS LUNG CANCER SCREENING Douglas E. Wood, MD, FACS, FRCSEd / Chair Ella A. Kazerooni, MD, MS / Vice-Chair Scott Baum, MD Georgie A. Eapen, MD David S. Ettinger, MD, FACP, FCCP Kathryn A. Gold, MD Lifang Hou, MD, PhD David M. Jackman, MD Donald Klippenstein, MD Rohit Kumar, MD Rudy P. Lackner, MD Lorriana E. Leard, MD Inga T. Lennes, MD, MBA, MPH Ann N. Leung, MD Pierre P. Massion, MD Peter Mazzone, MD, MPH Case / Robert E. Merritt, MD David E. Midthun, MD Sudhakar Pipavath, MD Christie Pratt, DHSc, MA Varun Puri, MD, MSCI Chakravarthy Reddy, MD Mary E. Reid, PhD Roswell Park Arnold J. Rotter, MD City of Hope Peter B. Sachs, MD Matthew B. Schabath, PhD Mark L. Schiebler, MD Lynn Tanoue, MD Betty C. Tong, MD, MHS William D. Travis, MD Benjamin Wei, MD Stephen C. Yang, MD PROSTATE CANCER EARLY DETECTION Peter R. Carroll, MD, MPH / Chair J. Kellogg Parsons, MD, MHS / Vice-Chair Gerald Andriole, MD Robert R. Bahnson, MD Erik P. Castle, MD William J. Catalona, MD Douglas M. Dahl, MD John W. Davis, MD Jonathan I. Epstein, MD Ruth B. Etzioni, PhD Thomas A. Farrington, BSEE Patient Advocate George P. Hemstreet III, MD, PhD David Jarrard, MD Adam S. Kibel, MD Simon P. Kim, MD, MPH Case / NCCN As of December 31,

80 William Lowrance, MD, MPH Paul Maroni, MD James L. Mohler, MD Roswell Park Todd M. Morgan, MD Kelvin A. Moses, MD, PhD Robert B. Nadler, MD Michael Poch, MD Charles Scales, MD Terrence M. Shaneyfelt, MD, MPH Marc C. Smaldone, MD, MSHP Geoffrey Sonn, MD Preston C. Sprenkle, MD Robert Wake, MD Bertram Yuh, MD, MS City of Hope SUPPORTIVE CARE ADULT CANCER PAIN Robert A. Swarm, MD / Chair Judith A. Paice, PhD, RN, FAAN / Vice-Chair Doralina L. Anghelescu, MD Madhuri Are, MD Justine Yang Bruce, MD Sorin Buga, MD, FACP City of Hope Marcin Chwistek, MD, FAAHPM Charles S. Cleeland, PhD David Craig, PharmD Oscar A. deleon-casasola, MD Roswell Park Ellin Gafford, MD Arif Kamal, MD Mihir M. Kamdar, MD Susan LeGrand, MD Case / Sean Mackey, MD, PhD M. Rachel McDowell, MSN, ACNP-BC Natalie Moryl, MD Lisle M. Nabell, MD Suzanne A. Nesbit, PharmD, BCPS Michael W. Rabow, MD Elizabeth M. Rickerson, MD Eric Roeland, MD Jill Sindt, MD Karen L. Syrjala, PhD Susan G. Urba, MD Jeanie M. Youngwerth, MD ANTIEMESIS David S. Ettinger, MD, FACP, FCCP / Chair Michael J. Berger, PharmD, BCOP / Vice-Chair Jonathan Aston, PharmD, BCOP Sally Barbour, PharmD, BCOP, CPP Jason Bergsbaken, PharmD Debra Brandt, DO Jennie R. Crews, MD Eun Jeong Kim, PharmD, MS, BCOP, BCPS Steven Kirkegaard, PharmD Dwight D. Kloth, PharmD, BCOP, FCCP Kelsey Klute, MD NCCN As of December 31,

81 Ruth Lagman, MD, MBA, MPH, FAAHPM, FACP Case / Dean Lim, MD City of Hope Charles Loprinzi, MD Cynthia X. Ma, MD, PhD Victoria Maurer, MSN, OCN Laura Michaud, PharmD, BCOP, CMQ, FASHP Rudolph M. Navari, MD, PhD, FACP Kimberly Noonan, MS, ANP, RN, AOCN Grazyna Riebandt, PharmD, BCOP Roswell Park Eric Roeland, MD Hope S. Rugo, MD Lee S. Schwartzberg, MD, FACP Bridget Scullion, PharmD, BCOP John Timoney, PharmD, BCOP Susan G. Urba, MD CANCER- AND CHEMOTHERAPY- INDUCED ANEMIA George M. Rodgers III, MD, PhD / Chair Laura M. Alwan, PharmD, BCOP / Vice-Chair Maureen Achebe, MD Murat Arcasoy, MD Rondeep Brar, MD Erica Campagnaro, MD David Cella, PhD Peter F. Coccia, MD Jennifer R. Green, MD Andrea Hagemann, MD Michael V. Jaglal, MD, MS Eric H. Kraut, MD Mike Kroll, MD Johanna Lasala, MD Michael M. Millenson, MD, FACP Tim Miller, PharmD Anne T. Neff, MD Case / Cindy L. O'Bryant, PharmD Rekha Parameswaran, MD Rita Paschal, MD Candido E. Rivera, MD Joseph Rosenthal, MD City of Hope Satish Shanbhag, MBBS, MPH Ari VanderWalde, MD, MPH CANCER-ASSOCIATED VENOUS THROMBOEMBOLIC DISEASE Michael B. Streiff, MD, FACS / Chair Bjorn Holmstrom, MD / Vice-Chair Aneel Ashrani, MD, MS Paula L. Bockenstedt, MD Carolyn Chesney, MD John Fanikos, MBA, RPh Randolph B. Fenninger, JD Patient Advocate Annemarie E. Fogerty, MD Shuwei Gao, MD NCCN As of December 31,

82 Samuel Z. Goldhaber, MD Krishna Gundabolu, MBBS Paul Hendrie, MD, PhD Alfred Lee, MD, PhD Jason T. Lee, MD Janelle E. Mann, PharmD, BCOP Brandon McMahon, MD Michael M. Millenson, MD, FACP Colleen Morton, MBBCh Lalitha Nayak, MD Case / Thomas L. Ortel, MD, PhD Sadat Ozair, MD Roswell Park Rita Paschal, MD Sanford Shattil, MD Tanya Siddiqi, MD City of Hope Kristi J. Smock, MD Gerald Soff, MD Tzu-Fei Wang, MD Eliot Williams, MD Anaadriana Zakarija, MD CANCER-RELATED FATIGUE Ann M. Berger, PhD, AOCNS, APRN, FAAN / Chair Kathi Mooney, PhD, RN, FAAN / Vice-Chair Chandana Banerjee, MD City of Hope William S. Breitbart, MD Kristen M. Carpenter, PhD Young Chang, MD Charles S. Cleeland, PhD Vanna Dest, MSN, AOCNS, APRN Lori L. DuBenske, PhD Carmen P. Escalante, MD, FACP Carlos Fernandez-Robles, MD Sofia Garcia, PhD Catherine Jankowski, PhD Aminah Jatoi, MD Leigh E. Kinczewski, CNP Thomas W. LeBlanc, MD, MA, MHS Elizabeth T. Loggers, MD, PhD Belinda Mandrell, PhD, RN Susan McInnes, MD Case / Fremonta Meyer, MD Barbara Murphy, MD Oxana Palesh, PhD, MPH Steven C. Plaxe, MD, FACOG, FACS Michelle B. Riba, MD, MS Anna Roshal, MD Hope S. Rugo, MD Carolina Salvador, MD Nina Wagner, MD Michelle Walter, DO Roswell Park DISTRESS MANAGEMENT Jimmie C. Holland, MD / Chair Teresa L. Deshields, PhD / Vice-Chair Barbara L. Andersen, PhD NCCN As of December 31,

83 Ilana M. Braun, MD William S. Breitbart, MD Benjamin W. Brewer, PsyD Luke O. Buchmann, MD Matthew M. Clark, PhD Molly Collins, MD Cheyenne Corbett, PhD Kristine A. Donovan, PhD, MBA Stewart Fleishman, MD Consultant Sofia Garcia, PhD Donna B. Greenberg, MD Rev. George F. Handzo, MA, MDiv Consultant Laura Herald Hoofring, MSN, APRN Robin M. Lally, PhD, MS, RN, AOCN Sara Martin, MD Lisa McGuffey, PhD, JD William Mitchell, MD Laura J. Morrison, MD Oxana Palesh, PhD, MPH Francine A. Parnes, JD, MA Patient Advocate Janice P. Pazar, PhD, RN Michelle B. Riba, MD, MS Jaroslava Salman, MD City of Hope Rosa Scrivani, LCSW Roswell Park Moreen M. Shannon-Dudley, MBA, MSW Alan D. Valentine, MD Elizabeth Weinstein, MD, MS Case / MANAGEMENT OF IMMUNOTHERAPY-RELATED TOXICITY John A. Thompson, MD / Chair Julie Brahmer, MD, MSc / Vice-Chair Bryan J. Schneider, MD / Vice-Chair Stephanie C. Andrews, MS, ANP-BC, RN Philippe Armand, MD, PhD Marianne Davies, MSN, DNP, ACNP-BC, AOCNP David Dunnington, MA Patient Advocate Marc Ernstoff, MD Roswell Park Christopher J. Hoimes, MD Case / Mario E. Lacouture, MD Alexander Limkakeng, MD Frederick L. Locke, MD Nisha A. Mohindra, MD Jarushka Naidoo, MD Anthony J. Olszanski, MD, RPh Sandip P. Patel, MD Sunil A. Reddy, MD Mabel Ryder, MD Jeffrey A. Sosman, MD Yinghong Wang, MD, PhD Jedd Wolchok, MD, PhD MYELOID GROWTH FACTORS Jeffrey Crawford, MD / Chair Pamela S. Becker, MD, PhD / Vice-Chair Douglas W. Blayney, MD Peter Curtin, MD Shira Dinner, MD Thomas Fynan, MD NCCN As of December 31,

84 Ivana Gojo, MD Elizabeth A. Griffiths, MD Roswell Park Shannon M. Hough, PharmD, BCOP Dwight D. Kloth, PharmD, BCOP, FCCP David Kuter, MD, PhD Gary H. Lyman, MD, MPH, FRCP Mary Mably, RPh, BCOP Sudipto Mukherjee, MD, PhD, MPH Case / Shiven Patel, MD Lia E. Perez, MD Adam Poust, PharmD Raajit Rampal, MD, PhD Vivek Roy, MD Hope S. Rugo, MD Ayman A. Saad, MD Lee S. Schwartzberg, MD, FACP Sepideh Shayani, PharmD, BCOP City of Hope Mahsa Talbott, PharmD Saroj Vadhan-Raj, MD Sumithira Vasu, MBBS Martha Wadleigh, MD Peter Westervelt, MD, PhD PALLIATIVE CARE Maria Dans, MD / Chair Thomas J. Smith, MD, FAAHPM, FACP, FASCO / Vice-Chair Anthony Back, MD Justin N. Baker, MD, FAAHPM Jessica R. Bauman, MD Anna C. Beck, MD Susan Block, MD Toby C. Campbell, MD, MSCI Amy A. Case, MD, FAAHPM Roswell Park Shalini Dalal, MD Howard Edwards, MD Tom R. Fitch, MD Jennifer Kapo, MD Jean S. Kutner, MD, MSPH Charles Miller, MD Sumi Misra, MD William Mitchell, MD Diane G. Portman, MD, FAAHPM David Spiegel, MD Linda Sutton, MD Eytan Szmuilowicz, MD Jennifer Temel, MD Roma Tickoo, MD, MPH Susan G. Urba, MD Elizabeth Weinstein, MD, MS Case / Finly J. Zachariah, MD City of Hope PREVENTION AND TREATMENT OF CANCER-RELATED INFECTIONS Lindsey Baden, MD / Chair NCCN As of December 31,

85 Sankar Swaminathan, MD / Vice-Chair Nikolaos Almyroudis, MD Roswell Park Michael Angarone, DO Gayle Blouin, PharmD, BCOP Bernard C. Camins, MD Brenda Cooper, MD Case / Erik R. Dubberke, MD Ashley Engemann, PharmD, BCOP Alison G. Freifeld, MD John N. Greene, MD Kevin Gregg, MD Hana Hakim, MD, MS James I. Ito, MD City of Hope Mark E. Lustberg, MD, PhD Jose G. Montoya, MD Steven A. Pergam, MD, MPH Kenneth V. Rolston, MD Gowri Satyanarayana, MD Lucas Schulz, PharmD Susan K. Seo, MD Shmuel Shoham, MD Randy Taplitz, MD Jeffrey E. Topal, MD John W. Wilson, MD SMOKING CESSATION Peter G. Shields, MD / Chair Roy S. Herbst, MD, PhD / Vice-Chair Douglas Arenberg, MD Neal Benowitz, MD Laura Bierut, MD Paul M. Cinciripini, PhD Bradley Collins, PhD Sean David, MD, DPhil, SM James Davis, MD Brian Hitsman, PhD Margaret Lang, MSN Danielle E. McCarthy, PhD Elyse R. Park, PhD W. Thomas Purcell, MD, MBA Jill Selzle, PA-C Christine E. Sheffer, PhD Roswell Park Andrea Silber, MD Sharon Spencer, MD Tawee Tanvetyanon, MD, MPH Brian Tiep, MD City of Hope Hilary Tindle, MD, MPH James Urbanic, MD David Warner, MD Monica Webb Hooper, PhD Case / Benny Weksler, MD, MBA, FACS C. Will Whitlock, NP, RN Douglas E. Wood, MD, FACS, FRCSEd SURVIVORSHIP Crystal S. Denlinger, MD, FACP / Chair Tara Sanft, MD / Vice-Chair Scott Baker, MD, MS NCCN As of December 31,

86 Gregory A. Broderick, MD Wendy Demark-Wahnefried, PhD, RD Debra L. Friedman, MD, MS Mindy E. Goldman, MD Melissa M. Hudson, MD Nazanin Khakpour, MD, FACS Allison King, MD Divya Koura, MD Robin M. Lally, PhD, MS, RN, AOCN Terry S. Langbaum, MAS Allison L. McDonough, MD Michelle E. Melisko, MD Jose G. Montoya, MD Kathi Mooney, PhD, RN, FAAN Javid J. Moslehi, MD Tracey O'Connor, MD Roswell Park Linda Overholser, MD, MPH Electra D. Paskett, PhD Jeffrey Peppercorn, MD, MPH Alma Rodriguez, MD Kathryn J. Ruddy, MD, MPH Paula Silverman, MD Case / Sophia K. Smith, PhD, MSW Karen L. Syrjala, PhD Amye J. Tevaarwerk, MD Susan G. Urba, MD Mark T. Wakabayashi, MD, MPH City of Hope Phyllis C. Zee, MD, PhD Damon R. Reed, MD Steven Robinson, MBBS Abby R. Rosenberg, MD, MA, MS Tara Sanft, MD AGE-RELATED RECOMMENDATIONS ADOLESCENT AND YOUNG ADULT ONCOLOGY Peter F. Coccia, MD / Chair Alberto S. Pappo, MD / Vice-Chair Lynda Beaupin, MD Roswell Park Smita Bhatia, MD, MPH Virginia F. Borges, MD, MMSc Scott C. Borinstein, MD, PhD Rashmi Chugh, MD Shira Dinner, MD Jeanelle Folbrecht, PhD City of Hope Lindsay Frazier, MD, ScM Robert Goldsby, MD Alexandra Gubin, MSW Cancer Center at Johns Hopkins Robert Hayashi, MD Mary Huang, MD Michael P. Link, MD John A. Livingston, MD Yousif Matloub, MD Case / Frederick Millard, MD NCCN As of December 31,

87 Kevin C. Oeffinger, MD Diane Puccetti, MD Damon R. Reed, MD Steven Robinson, MBBS Abby R. Rosenberg, MD, MA, MS Tara Sanft, MD Margaret Von Mehren, MD Nicholas Yeager, MD OLDER ADULT ONCOLOGY Efrat Dotan, MD / Chair Louise C. Walter, MD / Vice-Chair Joel Baumgartner, MD Ilene S. Browner, MD Peggy Burhenn, MS, AOCNS, RN City of Hope Harvey Jay Cohen, MD Beatrice J. Edwards, MD, MPH Rodney Ellis, MD Case / Martine Extermann, MD, PhD Apar Kishor P. Ganti, MD Cary Gross, MD Emily J. Guerard, MD Joleen Hubbard, MD Arti Hurria, MD City of Hope Reshma Jagsi, MD, DPhil Nancy L. Keating, MD, MPH Elizabeth Kessler, MD Beatriz Korc-Grodzicki, MD, PhD June M. McKoy, MD, MBA, JD, MPH Bruno C. Medeiros, MD Tracey O'Connor, MD Roswell Park Cynthia Owusu, MD, MS Case / Ashley Rosko, MD Hope S. Rugo, MD Randall W. Rupper, MD, MPH Derek L. Stirewalt, MD William P. Tew, MD Noam VanderWalde, MD Tanya Wildes, MD Grant R. Williams, MD ADVISORY PANEL IMAGING Elliot K. Fishman, MD / Chair Samuel Achilefu, PhD Mahmoud M. Al-Hawary, MD Norbert E. Avril, MD Case / Jared Christensen, MD Dominique Delbeke, MD, PhD Pamela DiPiro, MD Kristin Dittmar, MD Sofia S. Haque, MD John M. Hoffman, MD Peter Loud, MD Roswell Park Desiree E. Morgan, MD NCCN As of December 31,

88 Charles H. Morris, MD Rosaleen Parsons, MD Scott Perlman, MD Trevor A. Rose, Jr., MD, MPH Dushyant W. Sahani, MD Cynthia Santillan, MD Claude B. Sirlin, MD Eric P. Tamm, MD Carolyn L. Wang, MD Jimmie Wong, MD City of Hope Vahid Yaghmai, MD, MS NCCN STAFF Margaret Abdalian Executive Assistant Jorge Bacigalupo Global Business Development Program Manager Kimberly Bayer CE Specialist Elyse Becker Senior Business Development Specialist Mary Ellen Benetz, CCRP Research Study Associate Mary Anne Bergman Guidelines Coordinator Kieran Berkery Business Development Coordinator Marian Birkeland, PhD Senior Director, Compendia Development Donna Black Administrative Coordinator Michael Blake, MSIS Associate Director, Information Technology Eileen C. Boscia, CPA, MBA Controller Katie Kiley Brown Manager, Corporate Communications Jennifer L. Burns Guidelines Coordinator Kimberly A. Callan, MS, ELS Senior Director, Professional & Patient Publications Kara Caltabiano Receptionist Robert W. Carlson, MD Chief Executive Officer Diana Cartwright, MHA Oncology Best Practices Project Analyst Sonia N. Castro Executive & Project Assistant Rachael Clarke Guidelines Data & Layout Coordinator Alycia Corrigan, BA, CCRP Medical Writer Susan D. Darlow, PhD Oncology Scientist/Medical Writer Rachel Darwin Manager, Public Relations Sarah DeVincenzo, PharmD, BCPS Oncology Scientist, Drugs & Biologics Programs Caitlin Donnelly Global Business Development Specialist Jean Marie Dougherty Executive Assistant Kimberly C. Drager Manager, Business Development Mary A. Dwyer, MS, CGC Senior Manager, Guidelines Anita M. Engh, PhD Oncology Scientist/Medical Writer Ellen Erkess Guidelines Data & Layout Coordinator Melissa Esplen Meeting Planner Patricia M. Esposito, MPH Senior Research & Business Development Associate Amanda Evangelista, MBA Senior Accountant C. Lyn Fitzgerald, MJ Senior Vice President, U.S. & Global Development Deborah A. Freedman-Cass, PhD Oncology Scientist/Senior Medical Writer Elisabeth Ganiszewski Human Resource Generalist Mark A. Geisler Director, Conferences & Meetings Kristina M. Gregory, RN, MSN, OCN Vice President, Clinical Information Operations Lisa A. Gurski, PhD Oncology Scientist/Medical Writer William Guthier IT Support Specialist Sandra Hammerschmidt Administrative/Project Specialist Evelyn Handel, PharmD, BCPS, BCOP Director, Drugs & Biologics Programs Laura J. Hanisch, PsyD Medical Writer/Patient Information Specialist Donald M. Harting, ELS, CHCP Manager, CE Grant Writing & Outcomes Genevieve M. Hartzman, MA Journal Production Specialist Kristin Kline Hasson Senior Manager, CE Media Programs June L. Henry, MBA Accounting Manager Erin Hesler Administrative/Project Assistant NCCN As of December 31,

89 Karin G. Hoffmann, RN, CCM Guidelines Coordinator Miranda Hughes, PhD Oncology Scientist/Senior Medical Writer Jessica L. Jarman Senior Financial Analyst Alyse Johnson-Chilla, MS Guidelines Data & Layout Coordinator Rose Joyce Senior Project Manager, Conferences & Meetings Joseph M. Junod, MBA Director, Information Technology Nicole A. Kamienski, BS, CCRP Research Study Associate Karen Kanefield, BA Manager, CE Accreditation & Program Operations Ann O. Karosas, RPh, BCOP Oncology Scientist, Drugs & Biologics Programs Susan Kidney Graphic Design Specialist Lisa G. Kimbro, CPA, MBA Senior Vice President, Finance/Chief Financial Officer Rashmi Kumar, PhD Director, Clinical Information Operations Peter A. J. Lamb, MS Medical Informaticist Linda L. Leach Vice President, Administration & Human Resources Megan LoBue Grant Writer Joseph P. MacAfee III Network & Computer Systems Administrator Heather Matt CE Project Manager James McCanney, JD Policy/Advocacy Fellow Robert McClain Lead.NET Application Developer Joan S. McClure, MS Senior Vice President, Clinical Information & Publications Kelly McClurg Accounts Payable Coordinator Nicole R. McMillian, MS, CHES Guidelines Coordinator Diane McPherson Meeting Planner Melanie A. Moletzsky Senior CE Specialist Donna Moncuso, MS, RN Director, Payer & Employer Outreach Susan M. Most, RN, BSN, MBA Director, Clinical Operations Jill A. Mullen, MPA Director, Member Relations Elizabeth A. Nardi, MS Quality of Oncology Care Fellow Barbara Ndoka Business Development Specialist Sharla Nesbitt Accounts Receivable Staff Accountant Briana O'Donnell Marketing Manager Ndiya Ogba, PhD Oncology Scientist/Medical Writer Lisa Perfidio, MS Manager, CE Supporter Outreach Rosemary Pfluger Administrative/Project Assistant Lenora Pluchino, PhD Oncology Scientist/Medical Writer Donna M. Powell, MS, CMD, RT(T) Oncology Scientist, Radiation Oncology Programs Marcie R. Reeder, MPH Executive Director, NCCN Foundation Liz Rieder Senior Registration Manager Kerrin Rosenthal, MA Assistant Managing Editor Shannon Ryan Senior Manager, Conferences & Meetings Carl Saalbach Human Resource Generalist Narender Sara.NET Application Developer Jillian L. Scavone, PhD Oncology Scientist/Senior Medical Writer Donna Scharff Research Study Associate Alyssa Schatz, MSW Director, Policy & Advocacy Lauren E. Seabury Senior Marketing Specialist Dorothy A. Shead, MS Director, Patient Information Operations Mark Shriver.NET Application Developer Jack T. Skinner, PhD Oncology Scientist, Imaging Compendium Kathy Ann Smith, CMP, CHCP Manager, CE Grant Writing & Project Management Susan Sommerville Executive Coordinator Jessica M. Sugalski, MPPA Senior Manager, Best Practices Program Hema Sundar, PhD Oncology Scientist/Senior Medical Writer Kathleen Townsend Associate Director, Information Technology Jennifer P. Tredwell, MBA Senior Director, Marketing Amy E. Tuten, PharmD, BCOP Oncology Scientist, Drugs & Biologics Programs Sherry L. Ulrich, MBA Market Insights Specialist Mary A. Visceglia, RN, BSN, OCN Oncology Nurse, Chemotherapy Template Development Amanda E. Visnick, RN, BSN, OCN Oncology Nurse, Chemotherapy Template Development Lee Waldner Administrative/Project Assistant Doreen Walker Administrative Assistant Gary J. Weyhmuller, MBA, SPHR Executive Vice President/ Chief Operating Officer Kimberly Williams Manager, Creative Services Katy Winckworth-Prejsnar, MPH Policy/Advocacy Fellow NCCN core values excellence collaboration respect integrity passion innovation NCCN NCCN core values represent the principles that we, the NCCN team, strive to embrace. As representatives of leading cancer centers, we believe that by exemplifying these ideals within our organization, we can improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. As of December 31,

90 NCCN NCCN 2017 ANNUAL REPORT Photo Credit: Laura Roberts Landino and John Landino, May

91 Empowering patients through ACCESS to comprehensive resources Patient and caregiver resources The NCCN Foundation, founded by NCCN in 2010 to empower people living with cancer and advance oncology innovation, supports the publication of a rapidly expanding library of patient education resources and funds promising young investigators at the forefront of innovation in cancer research. The library of NCCN Guidelines for Patients and NCCN Quick Guide sheets saw growth in 2017, with the publication of 24 new and updated patient resources. NCCN New NCCN Guidelines for Patients added to the library include: Distress Myeloproliferative Neoplasms Rectal Cancer Thyroid Cancer Waldenström s Macroglobulinemia 91

92 In collaboration with Kidney Cancer Association, the NCCN Guidelines for Patients : Kidney Cancer was translated into Chinese, Czech, German, and Spanish, to ensure that patients throughout the world have access to understandable treatment information. NCCN Foundation is proud to support these significant resources which indeed will empower patients with cancer and their caregivers to make informed choices about their care. We are incredibly grateful for the generous support from our sponsors, as their patronage gives patients access to the same treatment information that their doctors use." - Marcie R. Reeder, MPH, Executive Director, NCCN Foundation In addition to the new and translated patient guidelines, in 2017, the library included patient resources for: Acute Lymphocytic Leukemia Adolescents and Young Adults With Cancer Brain Cancer - Gliomas Breast Cancer Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Colon Cancer Diffuse Large B-cell Lymphoma Esophageal Cancer Follicular Lymphoma Hodgkin Lymphoma Kidney Cancer Lung Cancer Lung Cancer Screening Malignant Pleural Mesothelioma Mantle Cell Lymphoma Melanoma Multiple Myeloma Mycosis Fungoides Myelodysplastic Syndromes New cancer diagnosis? NCCN Foundation empowers you to make informed decisions at each step of your cancer journey. Let us be your guide Contact us patientguidelines@nccn.org NCCN 92

93 Nausea and Vomiting Ovarian Cancer Pancreatic Cancer Peripheral T-cell Lymphoma Prostate Cancer Soft Tissue Sarcoma Stomach Cancer In 2017, there were more than eight million page views of these invaluable resources by more than 395,000 individuals. As part of the NCCN Foundation s educational library, the NCCN Guidelines for Patients and NCCN Quick Guide tm sheets are all available free-of-charge on NCCN.org/patients, as well as on the NCCN Patient Guides for Cancer mobile app. NCCN Learn how these resources provided a true difference in the life of one patient, in particular: To view this patient story visit: NCCN.org/annualreport Craig Funcke and Tracy Pullar talk about using the NCCN Guidelines for Patients. 93

94 2017 NCCN Foundation Metrics 8,056,232 PAGE VIEWS OF NCCN GUIDELINES FOR PATIENTS NCCN 39 NCCN GUIDELINES FOR PATIENTS 43 NCCN QUICK GUIDE tm SHEETS 13 NCCN GUIDELINES FOR PATIENTS ADVOCACY SPONSORS 64 NCCN GUIDELINES FOR PATIENTS ADVOCACY ENDORSERS 100 % OF NCCN FOUNDATION BOARD ANNUAL APPEAL PARTICIPATION 60 % OF NCCN BOARD ANNUAL APPEAL PARTICIPATION 100 % OF NCCN STAFF ANNUAL APPEAL PARTICIPATION 94

95 Providing ACCESS to career enhancing funding to young investigators The NCCN Foundation Young Investigator Award has been critical in this early point in my research career. It has provided the support for the study, as well as protected my time as a researcher to build my research program in this area so that I can grow to become an independent researcher. - Christine Veenstra, MD, MSHP, University of Michigan Comprehensive Cancer Center, 2015 YIA recipient NCCN Foundation Young Investigator's Awards Improvement in care requires improved and enhanced cancer research. Over the past seven years, NCCN Foundation has granted more than $5.2 million to investigators from the NCCN Member Institutions who are early in their careers. Through a competitive process, the Foundation provides funding over a two-year period for research initiatives focused on assessing and improving outcomes in cancer. In 2017, NCCN Foundation awarded grants to the following young researchers: Kemi Doll, MD, MSCR,, Racial Disparities in Endometrial Cancer Saad Kenderian, MB, CHB,, Chimeric Antigen Receptor T-Cell Therapy in Chronic Lymphocytic Leukemia: Mechanisms of Resistance and Strategies to Enhance Efficacy Florian Muller, PhD, MD Anderson Cancer Center, ENO1-Deletion as a Target for Personalized Oncology: Collateral Lethality to the Clinic Elizabeth Stewart, MD, St. Jude Children s Research Hospital/ NCCN 95

96 University of Tennessee, Preclinical Match Liqin Zhu, PhD, St. Jude Children s Research Hospital/University of Tennessee, Patient-Derived Tumor Spheroids for High-Risk Hepatoblastoma Drug Discovery To view Dr. Johnson, visit NCCN.org/annualreport Two years following their awards, recipients of the NCCN Foundation Young Investigator Awards are invited to present their research during the General Poster Session at the NCCN Annual Conference. The following researchers, 2015 recipients, presented their initial data: Dr. Johnson, Vanderbilt Ingram Cancer Center on his award-winning research. James Blachly, MD, Cancer Center James Cancer Hospital, Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status Areej El-Jawahri, MD, Massachusetts General Hospital Cancer Center, A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors Douglas Johnson, MD,, Survivorship in Patients Receiving Immune Checkpoint Inhibitors Todd Morgan, MD, University of Michigan Comprehensive Cancer Center, Tissue-Based Genomics for Risk Stratification in Localized Renal Cell Carcinoma Christine Veenstra, MD, MSHP, Comprehensive Cancer Center, Partnered Status & Receipt of NCCN Guideline-Concordant Colon Cancer NCCN 96

97 2017 NCCN Foundation Young Investigator Awards Metrics NCCN 36 YOUNG INVESTIGATOR AWARDEES MEMBER ACTIVE YOUNG TOTAL FUNDING TO Name (Tracey)?? on using the NCCN Guidelines for Patients. INSTITUTIONS YOUNG INVESTIGATOR REPRESENTED AWARDEES INVESTIGATOR AWARDS STUDIES $5,200,000 97

98 The NCCN Foundation Board of Directors comprises volunteers with diverse background and experiences, all of whom share a passion for the mission of the NCCN Foundation to empower people living with cancer and advance oncology innovation. They generously volunteer their time to make a difference in the lives of patients with cancer. In March 2017, NCCN Foundation named Gena Cook, Co-Founder and Chief Executive Officer of Navigating Cancer, as Chair of the NCCN Foundation Board of Directors. Ms. Cook, who was elected to the Board in 2010, succeeds the Honorable Ellen O. Tauscher, who served as chair of the NCCN Foundation Board of Directors since NCCN Foundation also named Heather Kopecky, PhD, MBA, as Vice- Chair of the NCCN Foundation Board of Directors, succeeding Michael Parisi, MBA, MA, who served in the position since the Foundation s inception in BOARD OF DIRECTORS Gena Cook / Chair Navigating Cancer Heather J. Kopecky, PhD, MBA / Vice-Chair Korn Ferry International Ray Lynch, CPA, MBA / Treasurer Jack Gentile / Secretary Harborside Press, LLC Al B. Benson III, MD, FACP, FASCO Robert H. Lurie of Northwestern University Thomas A. D'Amico, MD Deborah Morosini, MD Loxo Oncology, Inc. Michael Parisi, MBA, MA Ogilvy CommonHealth Worldwide Denise Reinke, MS, NP Marc Samuels, JD, MPH ADVI Susan Stein, MPH CONNEXION Healthcare The Honorable Ellen O. Tauscher Baker, Donelson, Bearman, Caldwell & Berkowitz, PC Robert C. Young, MD RCY Medicine NCCN NCCN Foundation Board Officers (from right to left): Jack Gentile, Secretary; Heather Kopecky, Vice-Chair; Gena Cook, Chair; and Ray Lynch, Treasurer. FINANCE COMMITTEE Gena Cook Navigating Cancer Ray Lynch, CPA, MBA Susan Stein, MPH CONNEXION Healthcare As of December 31,